<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?subarticle report8788?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Res</journal-id><journal-id journal-id-type="iso-abbrev">F1000Res</journal-id><journal-id journal-id-type="pmc">F1000Research</journal-id><journal-title-group><journal-title>F1000Research</journal-title></journal-title-group><issn pub-type="epub">2046-1402</issn><publisher><publisher-name>F1000Research</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4457118</article-id><article-id pub-id-type="pmid">26097685</article-id><article-id pub-id-type="doi">10.12688/f1000research.5827.2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group><subject>Articles</subject><subj-group><subject>Cancer Therapeutics</subject></subj-group></subj-group></article-categories><title-group><article-title>Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity</article-title><fn-group content-type="pub-status"><fn><p>v2; ref status: indexed</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koltai</surname><given-names>Tomas</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><aff id="a1">
<label>1</label>Centro de Diagnostico y Tratamiento de la Obra Social del Personal de la Alimentaci&#243;n, Talar de Pacheco, Buenos Aires, 1618, Argentina</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:tkoltai@hotmail.com">tkoltai@hotmail.com</email></corresp><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>5</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>9</elocation-id><history><date date-type="accepted"><day>16</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#169; 2015 Koltai T</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license><license license-type="open-access" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="f1000research-4-6594.pdf"/><abstract><p>
<bold>Objective:</bold> To review the mechanisms of anti-cancer activity of nelfinavir and other protease inhibitors (PIs) based on evidences reported in the published literature.</p><p>
<bold>Methods:</bold> We extensively reviewed the literature concerning nelfinavir (NFV) as an off target anti-cancer drug and other PIs. A classification of PIs based on anti-cancer mode of action was proposed. Controversies regarding nelfinavir mode of action were also addressed.</p><p>
<bold>Conclusions:</bold> The two main mechanisms involved in anti-cancer activity are endoplasmic reticulum stress-unfolded protein response pathway and Akt inhibition. However there are many other effects, partially dependent and independent of those mentioned, that may be useful in cancer treatment, including MMP-9 and MMP-2 inhibition, down-regulation of CDK-2, VEGF, bFGF, NF-kB, STAT-3, HIF-1 alfa, IGF, EGFR, survivin, BCRP, androgen receptor, proteasome, fatty acid synthase (FAS), decrease in cellular ATP concentration and upregulation of TRAIL receptor DR5, Bax, increased radiosensitivity, and autophagy. The end result of all these effects is slower growth, decreased angiogenesis, decreased invasion and increased apoptosis, which means reduced proliferation and increased cancer cells death.</p><p>PIs may be classified according to their anticancer activity at clinically achievable doses, in AKT inhibitors, ER stressors and Akt inhibitors/ER stressors.</p><p>Beyond the phase I trials that have been recently completed, adequately powered and well-designed clinical trials are needed in the various cancer type settings, and specific trials where NFV is tested in association with other known anti-cancer pharmaceuticals should be sought, in order to find an appropriate place for NFV in cancer treatment.</p><p>The analysis of controversies on the molecular mechanisms of NFV hints to the possibility that NFV works in a different way in tumor cells and in hepatocytes and adipocytes.</p></abstract><kwd-group kwd-group-type="author"><kwd>Nelfinavir</kwd><kwd>protease inhibitor</kwd><kwd>cancer</kwd><kwd>endoplasmic reticulum stress</kwd><kwd>unfolded protein response</kwd><kwd>Akt</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement></funding-group></article-meta><notes notes-type="version-changes"><sec><label>Revised</label><title>Amendments from Version 1</title><p>In this version, a table was included listing past and ongoing clinical trials using nelfinavir in cancer treatment.</p></sec></notes></front><body><sec><title>Abbreviations</title><p>NFV: Nelfinavir</p><p>PI: HIV Protease Inhibitors</p><p>ERS: Endoplasmic reticulum stress</p><p>UPR: Unfolded protein response</p><p>BCRP: Breast cancer resistance protein</p><p>FAS: Fatty Acid Synthase</p></sec><sec sec-type="intro"><title>Introduction</title><p>In March 1997, the United States Food and Drug Administration (FDA) approved Nelvinavir (NFV, brand name Viracept) for HIV treatment in humans
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup>. NFV is a safe, orally available, and potent drug against HIV-1 and HIV-2
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup>. This protease inhibitor (PI) was developed by the private pharmaceutical sector and was a big success in the treatment of AIDS in association with other anti-retroviral drugs
<sup><xref rid="ref-3" ref-type="bibr">3</xref></sup>. The introduction of PIs combined with HIV reverse transcriptase inhibitors started the era of HAART (highly active anti-retroviral treatment) and is nowadays the standard of care in HIV-AIDS
<sup><xref rid="ref-4" ref-type="bibr">4</xref></sup>.</p><p>PIs inhibit HIV-1 and HIV-2 proteases (which are aspartate proteases), impeding virus replication and release of infecting viral particles from diseased cells. The mechanism of action of protease inhibitors involves competitive binding to the enzyme
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup>.</p><p>NFV is being progressively displaced from HIV therapeutics by second generation HIV PIs, but has shown interesting off target actions in cancer.</p><p>The possible use of anti-HIV drugs against cancer is not new: in the 1990s AZT (zidovudine or azidothymidine) was proposed as anti-neoplastic drug, but clinical trials did not confirm the preliminary good results obtained
<italic>in vitro</italic>
<sup><xref rid="ref-6" ref-type="bibr">6</xref></sup>.</p><p>That HIV PIs target other molecules besides the HIV protease is quite evident if we examine adverse effects like insulin resistance and lipodystrophy. These and other evidences such as inhibition of tumor cell production of cytokines, anti-angiogenesis, induction of apoptosis and others, suggest off targets effects for PIs, and hints to the concept of a new class of drugs against cancer with multiple anti-cancer effects
<sup><xref rid="ref-6" ref-type="bibr">6</xref></sup>.</p><p>NFV, the most important anti-cancer drug of the PI family, if repurposed for cancer treatment, would have an important advantage: it has been used for more than 15 years in HIV treatment and its safety, pharmacokinetics, and adverse events are well known. Serious adverse events are not common with the exception of diarrhea when used at high doses.</p><p>Research on NFV as a potentially useful drug for cancer treatment
<sup><xref rid="ref-6" ref-type="bibr">6</xref></sup> started in 2009.</p><p>In this article, we thoroughly review the literature published in this matter and analyze mainly the anti-cancer mechanisms of action of NFV.</p><p>Certain controversies regarding NFV activity in lipid metabolism will be considered in depth.</p></sec><sec><title>Evidences of nelfinavir anti-cancer activity</title><p>A partial response of Kaposi&#8217;s sarcoma patients to PIs was published in 1998
<sup><xref rid="ref-7" ref-type="bibr">7</xref></sup> and good results with regression (six complete responses out of 10 patients)
<sup><xref rid="ref-8" ref-type="bibr">8</xref></sup>. In 1999 Niehues
<italic>et al.</italic>
<sup><xref rid="ref-9" ref-type="bibr">9</xref></sup> published complete regression of Kaposi&#8217;s sarcoma in a child treated with highly active anti-retroviral therapy (HAART). Sgadari
<italic>et al.</italic> (2003) described also the inhibition of Kaposi&#8217;s sarcoma with protease inhibitors and they also mention that these drugs can antagonize vital properties of tumor cells like growth, invasion, tissue remodelling, angiogenesis and survival. They consider these effects to be a consequence of inhibition of invasion, matrix metalloprotease, proteasome and NF-&#954;B signaling
<sup><xref rid="ref-10" ref-type="bibr">10</xref></sup>. The possible mechanisms of PIs off target activity on tumor cells were described by pioneering work of Schmidtke
<italic>et al.</italic> in 1999
<sup><xref rid="ref-11" ref-type="bibr">11</xref></sup>: they observed that ritonavir was a modulator of proteasomal activity, allowed normal proliferation when used at low concentrations, but affected protein degradation when present at higher concentrations, and cell cycle was arrested.</p><p>Ikezoe
<italic>et al.</italic>
<sup><xref rid="ref-12" ref-type="bibr">12</xref></sup> described that protease inhibitors increased cellular growth inhibition of all transretinoic acid (ATRA) on cell cultures of myelocitytic leukaemia lines. Protease inhibitors also increased differentiation of acute myeloid leukemia cell lines.</p><p>In 2004, Ikezoe
<sup><xref rid="ref-13" ref-type="bibr">13</xref></sup> described the mechanisms involved in anti-cancer activity of protease inhibitors in myeloma cells.</p><p>The mechanisms involved in PIs anti-cancer activity are summarized in chronological order on
<xref ref-type="table" rid="T1">Table 1</xref>.</p><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1. </label><caption><title>Mechanisms of action of Nelvinavir and other PIs in cancer.</title></caption></table-wrap></sec><sec><title>Nelfinavir and the ERS-UPR pathway</title><p>NFV inhibits the proteases S1P and S2P that are involved in SREBP-1 maturation and other proteases necessary for protein maturation and folding (yet not fully identified) in the endothelial reticulum
<sup><xref rid="ref-49" ref-type="bibr">49</xref></sup>.</p><p>Activation of the unfolded protein response (UPR) starts in the ER when abnormal accumulation of protein is detected
<sup><xref rid="ref-57" ref-type="bibr">57</xref></sup>. This was investigated thoroughly in yeasts where detection of abnormal protein occurs through Ire1p/Ern1p-mediated signaling from the ER (in mammals there are three sensor proteins IRE1&#945;, PERK and ATF6
<sup><xref rid="ref-58" ref-type="bibr">58</xref></sup>). UPR activation leads to the specific removal of 252 nucleotides intron from a precursor mRNA of the transcription factor HAC-1p, and the resulting mature mRNA HAC-1p is translated to produce active HAC-1p. This transcription factor translocates to the nucleus and promotes the transcription of chaperones like GRP78 that facilitates removal of abnormal proteins from the ER through retrotranslocation and final disposal by the ubiquitin-proteasome pathway
<sup><xref rid="ref-59" ref-type="bibr">59</xref></sup>.</p><p>HAC1 precursor mRNA is constitutively expressed but not translated until Ire1p/Ern1p sensor removes the necessary nucleotides.</p><p>Thus the UPR is an intracellular signaling pathway where the ER &#8220;informs&#8221; the nucleus on the need to increase the levels of molecular chaperones and folding enzymes in order to maintain the ER homeostasis. Therefore UPR keeps unfolded proteins in the ER until they are correctly folded before they can go to their final destination. NFV seems to produce cellular stress by accumulation of misfolded or abnormal proteins in the ER, overwhelming the normal ER protein folding machinery
<sup><xref rid="ref-60" ref-type="bibr">60</xref></sup>. Chaperones bound to unfolded proteins in the ER initiate protein kinase cascades that inhibit translation, reverse translocation, activate ubiquitination enzymes, induce autophagia, and when stress is extreme, induce apoptosis.</p></sec><sec><title>Mechanism of action of Nelfinavir in cancer</title><fig fig-type="figure" id="f1" orientation="portrait" position="float"><label>Figure 1. </label><caption><title>Simplified mechanisms of action of nelfinavir in cancer.</title><p>ERS: Endoplasmic reticulum stress.</p></caption><graphic xlink:href="f1000research-4-6594-g0000"/></fig><fig fig-type="figure" id="f2" orientation="portrait" position="float"><label>Figure 2. </label><caption><title>A more detailed view of nelfinavir&#8217;s action on ER stress.</title></caption><graphic xlink:href="f1000research-4-6594-g0001"/></fig><fig fig-type="figure" id="f3" orientation="portrait" position="float"><label>Figure 3. </label><caption><title>Nelfinavir inhibition of SREBP1 as a cause of endoplasmic reticulum stress (ERS).</title><p>For this figure the model of nelfinavir in liposarcoma was used.</p></caption><graphic xlink:href="f1000research-4-6594-g0002"/></fig><fig fig-type="figure" id="f4" orientation="portrait" position="float"><label>Figure 4. </label><caption><title>SREBP is synthesized as an ER transmembrane protein and transported to the Golgi upon appropriate stimulus.</title><p>For activation of SREBP it is necessary that luminal S1P (a protease) cleaves first, followed by intramembrane S2P (another protease) to liberate the transcriptionally active amino-terminal segments of nSREBP. NFV inhibits S1P and S2P, so that transcriptionally active SREBP is not produced. Accumulation of inactive SREBP is one of the UPR initiators.</p></caption><graphic xlink:href="f1000research-4-6594-g0003"/></fig><table-wrap id="T2" orientation="portrait" position="anchor"><label>Table 2. </label><caption><title>Nelfinavir anti-cancer activity in different tumor tissues*.</title></caption><table-wrap-foot><fn><p>*Saquinavir-NO has been tested in human melanoma cells with good results
<sup><xref rid="ref-77" ref-type="bibr">77</xref></sup>.</p><p>**It is necessary to underscore the finding that cancer stem cells expressing embryonic genes like Oct4, Sox2 and others, are particularly prone to apoptosis when PIs are used, particularly iopinavir (nelfinavir and saquinavir are also effective in this matter).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="anchor"><label>Table 3. </label><caption><title>Summary of clinical trials performed with NFV as an anti-cancer drug.</title></caption></table-wrap><fig fig-type="figure" id="f5" orientation="portrait" position="float"><label>Figure 5. </label><caption><title>Summary of NFV anti-cancer mechanisms.</title></caption><graphic xlink:href="f1000research-4-6594-g0004"/></fig></sec><sec><title>Interactions of NFV and PIs with other drugs</title><p>Indinavir and NFV increase anti-malarial action of artemisinin
<italic>in vitro</italic> on
<italic>Plasmodium falciparum</italic>
<sup><xref rid="ref-78" ref-type="bibr">78</xref></sup>, but artemisinin has also an off target anti-cancer activity. Thus it is reasonable to raise the question: may the association of artesiminin with NFV increase anti-cancer activity?</p><p>Another research team
<sup><xref rid="ref-70" ref-type="bibr">70</xref></sup> has included both, NFV and artesiminin, in a multidrug repurposed protocol (CUSP 9) for the treatment of relapsed glioblastoma.</p><p>Celecoxib is an ER stressor that may enhance NFV anti-tumor activity
<sup><xref rid="ref-79" ref-type="bibr">79</xref></sup>.</p><p>Chloroquine and hydroxicloquine are autophagy inhibitors and may work synergistically with NFV, down-regulating autophagy and increasing apoptosis
<sup><xref rid="ref-70" ref-type="bibr">70</xref>,
<xref rid="ref-80" ref-type="bibr">80</xref></sup>.</p><p>Nelfinavir may produce overproduction of mcl1 through upregulation of Erk &#189;, which would reduce apoptosis. The problem can be solved adding sorafenib
<sup><xref rid="ref-81" ref-type="bibr">81</xref>,
<xref rid="ref-82" ref-type="bibr">82</xref></sup>.</p><p>In breast cancer cells, tamoxifen enhances anti-cancer activity of NFV
<sup><xref rid="ref-83" ref-type="bibr">83</xref></sup>. This synergism was independent of the estrogen receptor status so that the authors consider that the association of NFV and tamoxifen may be advantageous even in patients with no hormone responsive tumors.</p><p>Saquinavir has an interesting off target effect: it decreases intracellular ATP in adipocytes
<sup><xref rid="ref-56" ref-type="bibr">56</xref></sup>. If this effect is similar in tumor cells, an association with metformin and 2-deoxyglucose may produce anti-cancer activity
<sup><xref rid="ref-84" ref-type="bibr">84</xref>&#8211;
<xref rid="ref-86" ref-type="bibr">86</xref></sup>. There is growing interest on metabolic perturbators in cancer therapy and saquinavir may play a role in this field.</p></sec><sec><title>Clinical trials</title><p>A phase I dose escalation trial performed in 2014
<sup><xref rid="ref-87" ref-type="bibr">87</xref></sup> established a MTD (maximum tolerated dose) of 3125 mg twice daily and described that 45% of patients with solid tumors treated with this dose decreased AKT activity and increased ERS indicators. This indicated a possible benefit in neuroendocrine tumor patients and also established that dose limiting toxicity consists in neutropenia.</p><p>The dose (3125 mg bid) is more than twice the dose used in HIV treatment. But lower doses, in the range of those used in HIV treatment have been tested, combining nelfinavir with chemoradiotherapy in pancreatic cancer with evidence of efficacy
<sup><xref rid="ref-88" ref-type="bibr">88</xref></sup>. No control group was used in this research, so comparison was established with known data from previous publications, mainly the favourable possibility of tumor resection after treatment.</p><p>Even lower doses (625 mg and 1250 mg bid) were tested in a phase I trial of NSCLC in stages IIIA/IIIB combined with chemoradiotherapy
<sup><xref rid="ref-89" ref-type="bibr">89</xref></sup>. In nine out of 12 patients a PET scan was available post-treatment with 100% overall response (56% complete response and 44% partial response). Unfortunately, in this trial there was no control group; 50% of the patients (six out of 12) lived for more than 22 months after treatment; 25% (three out of 12) lived without disease for more than 32 months. The results may be considered favourable, even without a control group.</p><p>Buijsen
<italic>et al.</italic>
<sup><xref rid="ref-75" ref-type="bibr">75</xref></sup> recommend a dose of 750 mg NFV bid for a phase II trial of this drug in combination with chemoradiotherapy in locally advanced rectal cancer.</p><p>Ongoing phase II trials are mainly in myeloma (associated with bortezomib or lenalomide), glioblastoma patients (associated with chemoradiation), pancreas (associated with gemcitabine and radiation) and lung. (See
<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>).</p><p>The first results of clinical trials did not show a meaningful improvement in the outcome of patients with refractory adenoid cystic carcinoma which is a malignant salivary gland tumor which usually has a poor prognosis. In this case NFV was used as monotherapy
<sup><xref rid="ref-76" ref-type="bibr">76</xref></sup>.</p></sec><sec><title>Why nelfinavir has a role to play in cancer therapy?</title><p>Akt activation is an important step in cancer phenotype and is a key player in acquisition and maintenance of cancer hallmarks. Akt is a nodal regulator of cellular survival pathways
<sup><xref rid="ref-90" ref-type="bibr">90</xref></sup>. There are no drugs at the present time that can inhibit this protein with a good safety profile. Wortmannin, perifosine and other chemicals designed for PI3K/Akt inhibition were too toxic for clinical use or have shown disappointing results, so they did not enter the medical practice. Insulin stimulation of Akt phosphorylation was reduced by 55% at achievable doses
<sup><xref rid="ref-20" ref-type="bibr">20</xref></sup>. At the same time there is clear evidence that it favours apoptosis and growth inhibition at clinically tolerable and achievable doses.</p><p>This anti-Akt activity of NFV can be reinforced by concomitant mTOR inhibition which results in synergistic cytotoxicity
<sup><xref rid="ref-63" ref-type="bibr">63</xref></sup>. This may be due to the fact that mTOR inhibition without Akt inhibition eliminates a negative biofeedback loop on Akt, producing increased phoshorilation of Akt
<sup><xref rid="ref-91" ref-type="bibr">91</xref></sup>. According to Sarbassov
<sup><xref rid="ref-92" ref-type="bibr">92</xref></sup> this negative feedback is born in the mTORC2 complex.</p><p>According to Carracedo
<sup><xref rid="ref-93" ref-type="bibr">93</xref></sup>, this negative feedback loop goes as far as PI3K (
<xref ref-type="fig" rid="f6">Figure 6</xref>).</p><fig fig-type="figure" id="f6" orientation="portrait" position="float"><label>Figure 6. </label><caption><title>Negative feedback loop.</title></caption><graphic xlink:href="f1000research-4-6594-g0005"/></fig><p>mTOR inhibitors have become a new and important tool against cancer, for example in renal cell carcinoma. But the negative biofeedback loop on Akt must be solved to achieve really good results. NFV could be the clue.</p><fig fig-type="figure" id="f7" orientation="portrait" position="float"><label>Figure 7. </label><caption><title>Mechanism of synergy between NFV and mTOR inhibitors.</title><p>At the left is depicted the pathway under normal or pathological circumstances; in the middle drawing mTOR inhibition is counterbalanced by Akt activation due to loss of the negative biofeedback circuit; on the right, inhibition of both, mTOR and Akt may result in increased anti-cancer results.</p></caption><graphic xlink:href="f1000research-4-6594-g0006"/></fig><p>But the most important anti-tumor activity of NVR is not limited to Akt inhibition but ER stress and UPR which may be one of the pathways leading to apoptosis
<sup><xref rid="ref-94" ref-type="bibr">94</xref></sup>.</p><p>Additional features of NFV and other protease inhibitors are</p><list list-type="simple"><list-item><label>1)</label><p>the ability to sensitize cancer cells to chemoradiotherapy,</p></list-item><list-item><label>2)</label><p>anti-angiogenesis by decreasing VEGF/HIF expression,</p></list-item><list-item><label>3)</label><p>decreased expression of FAS (fatty acid synthase),</p></list-item><list-item><label>4)</label><p>the combination of radiation and PIs is well tolerated
<sup><xref rid="ref-39" ref-type="bibr">39</xref>,
<xref rid="ref-94" ref-type="bibr">94</xref></sup>,</p></list-item><list-item><label>5)</label><p>NFV cancer cell killing ability can easily be enhanced with other ER stressors like celecoxib
<sup><xref rid="ref-79" ref-type="bibr">79</xref></sup>. Cho
<italic>et al.</italic> found enhanced killing of chemoresistant breast cancer cells after celecoxib treatment that aggravated ER stress; perillyl alcohol is another stress aggravator that has been used with that purpose
<sup><xref rid="ref-96" ref-type="bibr">96</xref></sup>,</p></list-item><list-item><label>6)</label><p>In head and neck cancer related to HPV, NFV produced down-regulation of Akt and radiosensitization
<sup><xref rid="ref-97" ref-type="bibr">97</xref></sup>,</p></list-item><list-item><label>7)</label><p>NFV not only down-regulates Akt but also MAPK (in adenoid cystic cancer)
<sup><xref rid="ref-98" ref-type="bibr">98</xref></sup>, and retards oral cell proliferation including normal keratinocytes and squamous cell cancer
<sup><xref rid="ref-99" ref-type="bibr">99</xref></sup>,</p></list-item><list-item><label>8)</label><p>There are evidences, at least in pancreatic cancer, that NFV dependent down-regulation of Akt is independent of the mutational status of K-ras
<sup><xref rid="ref-100" ref-type="bibr">100</xref></sup>,</p></list-item><list-item><label>9)</label><p>There is clear evidence (in glioblastoma) of the relation between NFV and apoptosis through the following pathway
<sup><xref rid="ref-46" ref-type="bibr">46</xref></sup>:</p></list-item></list><p>
<mml:math id="m1"><mml:mrow><mml:menclose notation="box" style="color: #000000"><mml:mtext mathcolor="#000000">NFV------ER stress--------CHOP------up regulation of TRAIL receptor DR5</mml:mtext></mml:menclose></mml:mrow></mml:math>
</p><list list-type="simple"><list-item><label>10)</label><p>Down-regulation of MMP-9 (reduced expression and secretion of MMP-9 by human preadipocytes)
<sup><xref rid="ref-64" ref-type="bibr">64</xref>,
<xref rid="ref-101" ref-type="bibr">101</xref></sup>,</p></list-item><list-item><label>11)</label><p>Increased apoptosis by NFV when associated with anti-autophagy drugs like chloroquine or hydroxychloroquines, particularly in triple negative breast cancer cells
<sup><xref rid="ref-102" ref-type="bibr">102</xref></sup>.</p></list-item></list></sec><sec><title>Possible controversies</title><p>The SREBP pathway for regulation of fat metabolism is initiated through proteolytic cleavage of precursor forms of the SREBPs (125 Kd protein) in ER membranes. When cells are in need of sterol, the precursor SREBPs are hydrolyzed by a 2-step mechanism involving membrane-bound serine protease S1P and a metalloprotease S2P. The N-terminal fragment of SREBP (nSREBP) is a 68 Kd protein that translocates to the nucleus where it works as a promoter-enhancer, binding to sterol regulatory elements located in DNA and activates gene transcription (
<xref ref-type="fig" rid="f4">Figure 4</xref>). The nuclear SREBP can be rapidly degraded by a proteasome-mediated mechanism. This provides regulation of gene transcriptional activities
<sup><xref rid="ref-103" ref-type="bibr">103</xref></sup>.</p><p>Transgenic mice over-expressing the constitutively active nuclear forms of the SREBPs (nSREBPs) revealed that overexpression of SREBP-1 or SREBP-2 leads to activation of genes involved in the cholesterol and fatty acid biosynthesis cascades. These transgenic mice displayed the classical features of generalized lipodystrophy, similar to those found in patients under PI therapy
<sup><xref rid="ref-104" ref-type="bibr">104</xref></sup>.</p><p>Riddle
<italic>et al.</italic> in 2001
<sup><xref rid="ref-105" ref-type="bibr">105</xref></sup> found that PI therapy (they used ritonavir) induced the accumulation of activated SREBP-1 and SREBP-2 in the nucleus of liver and adipose tissues. As a consequence, fatty acid and cholesterol biosynthesis were increased in these tissues. The authors consider that lipodystrophy, hyperlipidemia, and insulin resistance, are the consequence of activated SREBP-1 and SREBP-2 accumulation in the nucleus of liver and adipose tissues. The possible mechanism for these events, according to their criteria is PI suppression of activated SREBP degradation in the nucleus. In summary, Riddles&#8217;s study showed that ritonavir induced lipid metabolism abnormalities through stabilization of activated SREBP-1 and SREBP-2 in the nucleus of liver and adipose tissues.</p><p>These findings are in contrast with those of Guan
<sup><xref rid="ref-49" ref-type="bibr">49</xref>,
<xref rid="ref-106" ref-type="bibr">106</xref></sup> where NFV inhibited the nuclear translocation of the sterol regulatory element binding protein-1 (SREBP-1) in castration resistant prostate cancer and liposarcoma through inhibition of S1P. This led to accumulation of unprocessed SREBP-1.</p><p>Riddle
<italic>et al.</italic> described accumulation of processed SREBP-1 in the liver and adipose tissue while Guan found accumulation of unprocessed SREBP1 in ER and Golgi with no translocation to nucleus in liposarcoma and castration resistant prostate cancer tissue.</p><p>The controversy may be explained in the following way:
<list list-type="simple"><list-item><label>1)</label><p>There are three different isoforms of SREBP: SREBP-1a, SREBP-1c and SREBP-2.</p></list-item><list-item><label>2)</label><p>SREBP-1a and -1c have different expression profiles: SREBP-1a is highly expressed in proliferating cells, such as cancer cells, while SREBP-1c is the predominant form in normal cells, particularly hepatocytes
<sup><xref rid="ref-104" ref-type="bibr">104</xref></sup>.</p></list-item><list-item><label>3)</label><p>The target genes for the three SREBP isoforms are different.</p></list-item><list-item><label>4)</label><p>Riddle
<italic>et al.</italic> found increased SREBP-1 and two in the nucleus of liver and adipose tissues; these SREBPs are the active form (they make no difference between SREBP-1a and SREBP-1c).</p></list-item><list-item><label>5)</label><p>Guan
<italic>et al.</italic> found increased SREBP in Golgi in the inactive form (precursor) of tumor tissues treated with NFV.</p></list-item><list-item><label>6)</label><p>It is possible that tumor tissues that overexpress SREBP-1a behave in a different way than liver and adipose tissue that overexpress SREBP-1c.</p></list-item><list-item><label>7)</label><p>Riddle
<italic>et al.</italic> tested ritonavir and Guam
<italic>et al.</italic> tested NFV, so the pharmacological effects between these PIs may differ.</p></list-item></list>
</p><p>A second controversy that stems from the one described above is on the effect of NFV on FAS:
<list list-type="simple"><list-item><label>1)</label><p>According to Guan
<italic>et al.</italic>
<sup><xref rid="ref-106" ref-type="bibr">106</xref></sup>, NFV decreases expression of FAS in liposarcoma cells and castrate resistant prostate cancer as was depicted in
<xref ref-type="fig" rid="f3">Figure 3</xref>.</p></list-item><list-item><label>2)</label><p>According to Lenhard
<italic>et al.</italic> 2000
<sup><xref rid="ref-107" ref-type="bibr">107</xref></sup>, NFV increases expression of FAS in HepG2 cells (which show many of the normal biochemical functions of non tumor liver parenchymal cells).</p></list-item></list>
</p><p>May this difference be due to tissue-specific effects of NFV? Does NFV have different effects in tumor tissues and normal tissues?</p><p>To definitely solve these controversies, it is necessary to proceed with further experimental research, but the findings described above necessarily raise the doubt that mechanisms that work in tumor cells might be slightly different from those working in hepatocytes and adipocytes.</p></sec><sec><title>Possible negative aspects of PIs in cancer</title><p>Despite the anti-cancer activity of NFV and PIs, these drugs do not reduce the risk of developing cancer in HIV population
<sup><xref rid="ref-108" ref-type="bibr">108</xref></sup> and also exert certain depression of immunological functions, interfering with the differentiation program of monocytes into dendritic cells
<sup><xref rid="ref-109" ref-type="bibr">109</xref></sup>.</p><p>PIs increase the expression of P-glycoprotein (ABCB1) in Kaposi&#8217;s sarcoma cell lines increasing the multidrug resistance phenotype
<sup><xref rid="ref-110" ref-type="bibr">110</xref></sup>. At the same time ABCB1 expression depends on Akt activation
<sup><xref rid="ref-111" ref-type="bibr">111</xref></sup> and NFV inhibits partially Akt. The final result of the two antagonistic aspects requires further research.</p><p>There are well known undesirable side effects with HIV PIs, like hyperlipidemia, insulin resistance and lypodystrophy (peripheral fat wasting and excessive central fat deposition). One of the main responsible mechanisms of these side effects is the suppression of the breakdown of SREBP in the liver and adipose tissues resulting in increased fatty acid and cholesterol biosynthesis. SREBP accumulation in adipose tissue causes lipodystrophy.</p><p>PIs suppress proteasome-mediated breakdown of nascent apolipoprotein (apo) B, resulting in the overproduction of triglyceride. Finally, PIs also suppress the inhibition of the glucose transporter GLUT-4 activity in adipose tissue and muscle. This contributes directly to insulin resistance and diabetes
<sup><xref rid="ref-112" ref-type="bibr">112</xref></sup>.</p><p>Hepatomegaly and hepatic steatosis are direct consequences of the metabolic alterations explained above
<sup><xref rid="ref-105" ref-type="bibr">105</xref></sup>.</p></sec><sec><title>New PIs with anti-cancer activity</title><p>In 2010 You
<italic>et al.</italic>
<sup><xref rid="ref-113" ref-type="bibr">113</xref></sup> synthesized a new indinavir analogue with remarkable anti-cancer activity, similar to NFV: CH05-10. This drug achieved similar cytotoxity to NFV but at lower concentrations, against leukaemia, melanoma, ovarian and prostate cancer cell lines.</p><p>In 2009 Saquinavir-NO was introduced
<sup><xref rid="ref-114" ref-type="bibr">114</xref></sup>; it showed interesting anti-cancer properties in melanoma xenografts with significantly lower toxicity than saquinavir.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The most relevant mechanisms of PIs anti-cancer activity are Akt inhibition and ER stress.</p><p>Following our exhaustive analysis of the current medical literature we conclude that NFV anti-cancer activity is mainly dependent on ER stress-UPR.</p><p>Akt inhibition plays also a very important role but is not the unique or main source of anti-cancer effects.</p><p>The evidences that support these conclusions are:
<list list-type="simple"><list-item><label>1)</label><p>Even at very high doses of NFV (3,125 mg bid), Akt achieved a level of inhibition around 55% in cell culture
<sup><xref rid="ref-20" ref-type="bibr">20</xref></sup>.</p></list-item><list-item><label>2)</label><p>NFV is at the same time a strong ER stressor and an Akt inhibitor.</p></list-item><list-item><label>3)</label><p>Anti-cancer activity can be achieved at much lower doses than those necessary for Akt inhibition.</p></list-item><list-item><label>4)</label><p>Increasing ER stress by adding Celecoxib to NFV enhances cytotoxicity.</p></list-item><list-item><label>5)</label><p>Autophagy, which is one of the mechanisms cells use to survive increasing ER stress
<sup><xref rid="ref-115" ref-type="bibr">115</xref></sup>, is inhibited by adding chloroquine or hydroxychloroquine to NFV. In this case, apoptosis is significantly enhanced
<sup><xref rid="ref-80" ref-type="bibr">80</xref>,
<xref rid="ref-102" ref-type="bibr">102</xref></sup>.</p></list-item><list-item><label>6)</label><p>The PIs with anti-cancer activity like NFV, ritonavir
<sup><xref rid="ref-116" ref-type="bibr">116</xref></sup>, saquinavir
<sup><xref rid="ref-117" ref-type="bibr">117</xref></sup>, and the experimental drug CH05-10
<sup><xref rid="ref-113" ref-type="bibr">113</xref></sup> are strong ER stressors. Amprenavir is a PI that induces no ER stress and its anti-cancer activity is significantly weaker than that of NFV, although it has Akt inhibiting effects.</p></list-item><list-item><label>7)</label><p>Ritonavir, which is ER stressor, shows anti-cancer activity although it does not down-regulate Akt at concentrarions usually found in HIV patients
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>.</p></list-item><list-item><label>8)</label><p>Inhibition of proteasome with bortezomib has a synergistic effect with NFV apoptotic activity
<sup><xref rid="ref-118" ref-type="bibr">118</xref></sup>
</p></list-item><list-item><label>9)</label><p>PIs can be classified regarding anti-cancer activity at clinically achievable concentration in patients in
<list list-type="simple"><list-item><label>A)</label><p>Akt inhibitors only: e.g. amprenavir</p></list-item><list-item><label>B)</label><p>ER stressors only: e.g. ritonavir</p></list-item><list-item><label>C)</label><p>Akt inhibitors and ER stressors: examples NFV and experimental PI CH05-10. Of course this is the group that shows stronger anti-cancer activity.</p></list-item></list>
</p></list-item></list>
</p><p>There is enough evidence of NFV anti-cancer effects and there is adequate knowledge of how this activity works, so that NFV deserves well designed phase II clinical trials, as adjunct cancer therapy.</p><p>Associations with proteasomal inhibitors, celecoxib and other cell stressor should also be investigated in the clinical setting due to possible synergy. Tamoxifen with NFV may show interesting results in breast cancer.</p><p>Although a large amount of publications, including reviews, have been written on NFV and other PIs in cancer, none has been dedicated to a thorough examination and analysis of the mode of action of these pharmaceuticals as off target drugs (with the exception of the review by Gantt
<italic>et al.</italic>
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup>). It is hoped that this review will encourage an increment adequately powered and well-designed clinical trials in the various cancer types, beyond the phase I trials that have been recently performed, and specifically trials where these compounds may be tested in association with other known anti-cancer pharmaceuticals like NFV associated to bortezomib and hydroxychloroquine in myeloma, or mTOR inhibitors with NFV in HNSCC and many other possible combinations where the dual feature of NFV, ER stressor and Akt inhibitor, are required.</p><p>In myeloma NFV increases proteasome inhibition by bortezomib and may overcome resistance to proteasomal inhibitors. This is an action exclusive of NFV and not shared with other PIs
<sup><xref rid="ref-67" ref-type="bibr">67</xref></sup>, with the additional advantage that NFV shows the highest cytotoxic activity against primary myeloma cells.</p><p>If apoptosis is described as a cascade, then apoptosis stimulator drugs like NFV should be viewed as enhancers of this cascade. An initiator of the cascade is still necessary, for example chemoradiotherapy. After this initial step, apoptosis stimulator drugs increase the amount of cells entering this pathway. This might be one of possible reasons why nelfinavir alone has shown poor results in a clinical trial used as monotherapy.</p><p>This does not mean that NFV cannot act as an initiator, but the evidences show that it is prone to be an enhancer of apoptosis rather than an initiator.</p></sec><sec><title>Future directions</title><p>All the evidences presented in this review reinforce the concept that NFV is a useful drug in cancer treatment. It should be considered in association with chemoradiotherapy in the design of new protocols for diseases like multiple myeloma (in association with bortezomib and hydroxychloroquine) and prostate, pancreas and lung cancer where clinical trials are ongoing. New PIs are being developed with better anti-cancer profile like CH05-10 and saquinavir-NO
<sup><xref rid="ref-77" ref-type="bibr">77</xref></sup> and further development of new PIs with stronger anti-cancer activity, will probably go on in the future.</p></sec></body><back><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pai</surname><given-names>VB</given-names></name><name><surname>Nahata</surname><given-names>MC</given-names></name></person-group>:
<article-title>Nelfinavir mesylate: a protease inhibitor.</article-title>
<source><italic>Ann Pharmacother.</italic></source><year>1999</year>;<volume>33</volume>(<issue>3</issue>):<fpage>325</fpage>&#8211;<lpage>339</lpage>.
<pub-id pub-id-type="doi">10.1345/aph.18089</pub-id>
<?supplied-pmid 10200859?><pub-id pub-id-type="pmid">10200859</pub-id></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gantt</surname><given-names>S</given-names></name><name><surname>Casper</surname><given-names>C</given-names></name><name><surname>Ambinder</surname><given-names>RF</given-names></name></person-group>:
<article-title>Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.</article-title>
<source><italic>Curr Opin Oncol.</italic></source><year>2013</year>;<volume>25</volume>(<issue>5</issue>):<fpage>495</fpage>&#8211;<lpage>502</lpage>.
<pub-id pub-id-type="doi">10.1097/CCO.0b013e328363dfee</pub-id>
<!--<pub-id pub-id-type="pmcid">4029099</pub-id>-->
<?supplied-pmid 23872785?><pub-id pub-id-type="pmid">23872785</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flexner</surname><given-names>C</given-names></name></person-group>:
<article-title>HIV-protease inhibitors.</article-title>
<source><italic>N Engl J Med.</italic></source><year>1998</year>;<volume>338</volume>(<issue>18</issue>):<fpage>1281</fpage>&#8211;<lpage>1292</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJM199804303381808</pub-id>
<?supplied-pmid 9562584?><pub-id pub-id-type="pmid">9562584</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Volberding</surname><given-names>PA</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name></person-group>:
<article-title>Antiretroviral therapy for HIV infection: promises and problems.</article-title>
<source><italic>JAMA.</italic></source><year>1998</year>;<volume>279</volume>(<issue>17</issue>):<fpage>1343</fpage>&#8211;<lpage>1344</lpage>.
<pub-id pub-id-type="doi">10.1001/jama.279.17.1343</pub-id>
<?supplied-pmid 9582033?><pub-id pub-id-type="pmid">9582033</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>KE</given-names></name><name><surname>Wu</surname><given-names>E</given-names></name><name><surname>Patick</surname><given-names>AK</given-names></name><etal/></person-group>:
<article-title>Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.</article-title>
<source><italic>Antimicrob Agents Chemother.</italic></source><year>2001</year>;<volume>45</volume>(<issue>4</issue>):<fpage>1086</fpage>&#8211;<lpage>1093</lpage>.
<pub-id pub-id-type="doi">10.1128/AAC.45.4.1086-1093.2001</pub-id>
<!--<pub-id pub-id-type="pmcid">90428</pub-id>-->
<?supplied-pmid 11257019?><pub-id pub-id-type="pmid">11257019</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chow</surname><given-names>WA</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name></person-group>:
<article-title>Anti-HIV drugs for cancer therapeutics: back to the future?</article-title>
<source><italic>Lancet Oncol.</italic></source><year>2009</year>;<volume>10</volume>(<issue>1</issue>):<fpage>61</fpage>&#8211;<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(08)70334-6</pub-id>
<?supplied-pmid 19111246?><pub-id pub-id-type="pmid">19111246</pub-id></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krischer</surname><given-names>J</given-names></name><name><surname>Rutschmann</surname><given-names>O</given-names></name><name><surname>Hirschel</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Regression of&#160;Kaposi&#8217;s&#160;sarcoma&#160;during therapy with HIV-1 protease inhibitors: a prospective pilot study.</article-title>
<source><italic>J Am Acad Dermatol.</italic></source><year>1998</year>;<volume>38</volume>(<issue>4</issue>):<fpage>594</fpage>&#8211;<lpage>598</lpage>.
<pub-id pub-id-type="doi">10.1016/S0190-9622(98)70124-0</pub-id>
<?supplied-pmid 9555800?><pub-id pub-id-type="pmid">9555800</pub-id></mixed-citation></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lebb&#233;</surname><given-names>C</given-names></name><name><surname>Blum</surname><given-names>L</given-names></name><name><surname>Pellet</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi&#8217;s sarcoma.</article-title>
<source><italic>AIDS.</italic></source><year>1998</year>;<volume>12</volume>(<issue>7</issue>):<fpage>F45</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1097/00002030-199807000-00002</pub-id>
<?supplied-pmid 9619797?><pub-id pub-id-type="pmid">9619797</pub-id></mixed-citation></ref><ref id="ref-9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Niehues</surname><given-names>T</given-names></name><name><surname>Horneff</surname><given-names>G</given-names></name><name><surname>Megahed</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Complete regression of AIDS-related Kaposi&#8217;s sarcoma in a child treated with highly active antiretroviral therapy.</article-title>
<source><italic>AIDS.</italic></source><year>1999</year>;<volume>13</volume>(<issue>9</issue>):<fpage>1148</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1097/00002030-199906180-00026</pub-id>
<?supplied-pmid 10397553?><pub-id pub-id-type="pmid">10397553</pub-id></mixed-citation></ref><ref id="ref-10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sgadari</surname><given-names>C</given-names></name><name><surname>Monini</surname><given-names>P</given-names></name><name><surname>Barillari</surname><given-names>G</given-names></name><etal/></person-group>:
<article-title>Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.</article-title>
<source><italic>Lancet Oncol.</italic></source><year>2003</year>;<volume>4</volume>(<issue>9</issue>):<fpage>537</fpage>&#8211;<lpage>47. Review</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(03)01192-6</pub-id>
<?supplied-pmid 12965274?><pub-id pub-id-type="pmid">12965274</pub-id></mixed-citation></ref><ref id="ref-11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidtke</surname><given-names>G</given-names></name><name><surname>Holzhutter</surname><given-names>HG</given-names></name><name><surname>Bogyo</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>How an inhibitor of the HIV-I protease modulates proteasome activity.</article-title>
<source><italic>J Biol Chem.</italic></source><year>1999</year>;<volume>274</volume>(<issue>50</issue>):<fpage>35734</fpage>&#8211;<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.274.50.35734</pub-id>
<?supplied-pmid 10585454?><pub-id pub-id-type="pmid">10585454</pub-id></mixed-citation></ref><ref id="ref-12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikezoe</surname><given-names>T</given-names></name><name><surname>Daar</surname><given-names>ES</given-names></name><name><surname>Hisatake</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.</article-title>
<source><italic>Blood.</italic></source><year>2000</year>;<volume>96</volume>(<issue>10</issue>):<fpage>3553</fpage>&#8211;<lpage>9</lpage>.
<?supplied-pmid 11071654?><pub-id pub-id-type="pmid">11071654</pub-id></mixed-citation></ref><ref id="ref-13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikezoe</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Bandobashi</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.</article-title>
<source><italic>Mol Cancer Ther.</italic></source><year>2004</year>;<volume>3</volume>(<issue>4</issue>):<fpage>473</fpage>&#8211;<lpage>9</lpage>.
<?supplied-pmid 15078991?><pub-id pub-id-type="pmid">15078991</pub-id></mixed-citation></ref><ref id="ref-14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Groettrup</surname><given-names>M</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.</article-title>
<source><italic>Proc Natl Acad Sci U S A.</italic></source><year>1998</year>;<volume>95</volume>(<issue>22</issue>):<fpage>13120</fpage>&#8211;<lpage>13124</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.95.22.13120</pub-id>
<!--<pub-id pub-id-type="pmcid">23730</pub-id>-->
<?supplied-pmid 9789051?><pub-id pub-id-type="pmid">9789051</pub-id></mixed-citation></ref><ref id="ref-15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaedicke</surname><given-names>S</given-names></name><name><surname>Firat-Geier</surname><given-names>E</given-names></name><name><surname>Constantiniu</surname><given-names>O</given-names></name><etal/></person-group>:
<article-title>Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.</article-title>
<source><italic>Cancer Res.</italic></source><year>2002</year>;<volume>62</volume>(<issue>23</issue>):<fpage>6901</fpage>&#8211;<lpage>8</lpage>.
<?supplied-pmid 12460905?><pub-id pub-id-type="pmid">12460905</pub-id></mixed-citation></ref><ref id="ref-16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sgadari</surname><given-names>C</given-names></name><name><surname>Barillari</surname><given-names>G</given-names></name><name><surname>Toschi</surname><given-names>E</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.</article-title>
<source><italic>Nat Med.</italic></source><year>2002</year>;<volume>8</volume>(<issue>3</issue>):<fpage>225</fpage>&#8211;<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1038/nm0302-225</pub-id>
<?supplied-pmid 11875492?><pub-id pub-id-type="pmid">11875492</pub-id></mixed-citation></ref><ref id="ref-17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pajonk</surname><given-names>F</given-names></name><name><surname>Himmelsbach</surname><given-names>J</given-names></name><name><surname>Riess</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.</article-title>
<source><italic>Cancer Res.</italic></source><year>2002</year>;<volume>62</volume>(<issue>18</issue>):<fpage>5230</fpage>&#8211;<lpage>5</lpage>.
<?supplied-pmid 12234989?><pub-id pub-id-type="pmid">12234989</pub-id></mixed-citation></ref><ref id="ref-18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pajonk</surname><given-names>F</given-names></name><name><surname>McBride</surname><given-names>WH</given-names></name></person-group>:
<article-title>Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses.</article-title>
<source><italic>Radiother Oncol.</italic></source><year>2001</year>;<volume>59</volume>(<issue>2</issue>):<fpage>203</fpage>&#8211;<lpage>212</lpage>.
<pub-id pub-id-type="doi">10.1016/S0167-8140(01)00311-5</pub-id>
<?supplied-pmid 11325450?><pub-id pub-id-type="pmid">11325450</pub-id></mixed-citation></ref><ref id="ref-19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olson</surname><given-names>DP</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>D&#8217;Aquila</surname><given-names>RT</given-names></name><etal/></person-group>:
<article-title>The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).</article-title>
<source><italic>AIDS.</italic></source><year>2002</year>;<volume>16</volume>(<issue>13</issue>):<fpage>1743</fpage>&#8211;<lpage>1747</lpage>.
<pub-id pub-id-type="doi">10.1097/00002030-200209060-00005</pub-id>
<?supplied-pmid 12218384?><pub-id pub-id-type="pmid">12218384</pub-id></mixed-citation></ref><ref id="ref-20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>JQ</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Schutt</surname><given-names>M</given-names></name></person-group>:
<article-title>[Impairment of IRS-2 signaling in rat insulinoma INS-1 cells by nelfinavir].</article-title>
<source><italic>Zhejiang Da Xue Xue Bao Yi Xue Ban.</italic></source><year>2004</year>;<volume>33</volume>(<issue>4</issue>):<fpage>311</fpage>&#8211;<lpage>4</lpage>. Chinese.
<?supplied-pmid 15269981?><pub-id pub-id-type="pmid">15269981</pub-id></mixed-citation></ref><ref id="ref-21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Unadkat</surname><given-names>JD</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).</article-title>
<source><italic>J Pharmacol Exp Ther.</italic></source><year>2004</year>;<volume>310</volume>(<issue>1</issue>):<fpage>334</fpage>&#8211;<lpage>341</lpage>.
<pub-id pub-id-type="doi">10.1124/jpet.104.065342</pub-id>
<?supplied-pmid 15007102?><pub-id pub-id-type="pmid">15007102</pub-id></mixed-citation></ref><ref id="ref-22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piccinini</surname><given-names>M</given-names></name><name><surname>Rinaudo</surname><given-names>MT</given-names></name><name><surname>Anselmino</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.</article-title>
<source><italic>Antivir Ther.</italic></source><year>2005</year>;<volume>10</volume>(<issue>2</issue>):<fpage>215</fpage>&#8211;<lpage>23</lpage>.
<?supplied-pmid 15865215?><pub-id pub-id-type="pmid">15865215</pub-id></mixed-citation></ref><ref id="ref-23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Cerniglia</surname><given-names>GJ</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both
<italic>in vitro</italic> and
<italic>in vivo</italic>.</article-title>
<source><italic>Cancer Res.</italic></source><year>2005</year>;<volume>65</volume>(<issue>18</issue>):<fpage>8256</fpage>&#8211;<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1220</pub-id>
<?supplied-pmid 16166302?><pub-id pub-id-type="pmid">16166302</pub-id></mixed-citation></ref><ref id="ref-24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ikezoe</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells
<italic>in vitro</italic> and
<italic>in vivo</italic> in conjunction with blockade of androgen receptor STAT3 and AKT signaling.</article-title>
<source><italic>Cancer Sci.</italic></source><year>2005</year>;<volume>96</volume>(<issue>7</issue>):<fpage>425</fpage>&#8211;<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1349-7006.2005.00063.x</pub-id>
<?supplied-pmid 16053514?><pub-id pub-id-type="pmid">16053514</pub-id></mixed-citation></ref><ref id="ref-25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ikezoe</surname><given-names>T</given-names></name><name><surname>Nishioka</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.</article-title>
<source><italic>Br J Cancer.</italic></source><year>2006</year>;<volume>95</volume>(<issue>12</issue>):<fpage>1653</fpage>&#8211;<lpage>1662</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.bjc.6603435</pub-id>
<!--<pub-id pub-id-type="pmcid">2360758</pub-id>-->
<?supplied-pmid 17133272?><pub-id pub-id-type="pmid">17133272</pub-id></mixed-citation></ref><ref id="ref-26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chow</surname><given-names>WA</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Valdes-Albini</surname><given-names>F</given-names></name></person-group>:
<article-title>Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.</article-title>
<source><italic>Anticancer Drugs.</italic></source><year>2006</year>;<volume>17</volume>(<issue>8</issue>):<fpage>891</fpage>&#8211;<lpage>903</lpage>.
<pub-id pub-id-type="doi">10.1097/01.cad.0000224448.08706.76</pub-id>
<?supplied-pmid 16940799?><pub-id pub-id-type="pmid">16940799</pub-id></mixed-citation></ref><ref id="ref-27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pore</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Cerniglia</surname><given-names>GJ</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.</article-title>
<source><italic>Neoplasia.</italic></source><year>2006</year>;<volume>8</volume>(<issue>11</issue>):<fpage>889</fpage>&#8211;<lpage>95</lpage>.
<pub-id pub-id-type="doi">10.1593/neo.06535</pub-id>
<!--<pub-id pub-id-type="pmcid">1716015</pub-id>-->
<?supplied-pmid 17132220?><pub-id pub-id-type="pmid">17132220</pub-id></mixed-citation></ref><ref id="ref-28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pore</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Cerniglia</surname><given-names>GJ</given-names></name><etal/></person-group>:
<article-title>Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.</article-title>
<source><italic>Cancer Res.</italic></source><year>2006</year>;<volume>66</volume>(<issue>18</issue>):<fpage>9252</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1239</pub-id>
<?supplied-pmid 16982770?><pub-id pub-id-type="pmid">16982770</pub-id></mixed-citation></ref><ref id="ref-29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hampson</surname><given-names>L</given-names></name><name><surname>Kitchener</surname><given-names>HC</given-names></name><name><surname>Hampson</surname><given-names>IN</given-names></name></person-group>:
<article-title>Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells
<italic>in vitro</italic>.</article-title>
<source><italic>Antivir Ther.</italic></source><year>2006</year>;<volume>11</volume>(<issue>6</issue>):<fpage>813</fpage>&#8211;<lpage>25</lpage>.
<?supplied-pmid 17310826?><pub-id pub-id-type="pmid">17310826</pub-id></mixed-citation></ref><ref id="ref-30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben-Romano</surname><given-names>R</given-names></name><name><surname>Rudich</surname><given-names>A</given-names></name><name><surname>Etzion</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents.</article-title>
<source><italic>Antivir Ther.</italic></source><year>2006</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1051</fpage>&#8211;<lpage>1060</lpage>.
<?supplied-pmid 17302375?><pub-id pub-id-type="pmid">17302375</pub-id></mixed-citation></ref><ref id="ref-31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Samuleson</surname><given-names>CG</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.</article-title>
<source><italic>Neurosurg Focus.</italic></source><year>2007</year>;<volume>23</volume>(<issue>4</issue>):<fpage>E9</fpage>.
<pub-id pub-id-type="doi">10.3171/FOC-07/10/E9</pub-id>
<?supplied-pmid 17961046?><pub-id pub-id-type="pmid">17961046</pub-id></mixed-citation></ref><ref id="ref-32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Mikochik</surname><given-names>PJ</given-names></name><name><surname>Ra</surname><given-names>JH</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.</article-title>
<source><italic>Cancer Res.</italic></source><year>2007</year>;<volume>67</volume>(<issue>3</issue>):<fpage>1221</fpage>&#8211;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3377</pub-id>
<?supplied-pmid 17283158?><pub-id pub-id-type="pmid">17283158</pub-id></mixed-citation></ref><ref id="ref-33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Pore</surname><given-names>N</given-names></name><name><surname>Cerniglia</surname><given-names>GJ</given-names></name><etal/></person-group>:
<article-title>Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.</article-title>
<source><italic>Cancer Res.</italic></source><year>2007</year>;<volume>67</volume>(<issue>9</issue>):<fpage>4467</fpage>&#8211;<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3398</pub-id>
<?supplied-pmid 17483362?><pub-id pub-id-type="pmid">17483362</pub-id></mixed-citation></ref><ref id="ref-34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gills</surname><given-names>JJ</given-names></name><name><surname>Lopiccolo</surname><given-names>J</given-names></name><name><surname>Tsurutani</surname><given-names>J</given-names></name></person-group>:
<article-title>Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis
<italic>in vitro</italic> and
<italic>in vivo</italic>.</article-title>
<source><italic>Clin Cancer Res.</italic></source><year>2007</year>;<volume>13</volume>(<issue>17</issue>):<fpage>5183</fpage>&#8211;<lpage>94</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0161</pub-id>
<?supplied-pmid 17785575?><pub-id pub-id-type="pmid">17785575</pub-id></mixed-citation></ref><ref id="ref-35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cuneo</surname><given-names>KC</given-names></name><name><surname>Tu</surname><given-names>T</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors enhance the efficacy of irradiation.</article-title>
<source><italic>Cancer Res.</italic></source><year>2007</year>;<volume>67</volume>(<issue>10</issue>):<fpage>4886</fpage>&#8211;<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3684</pub-id>
<?supplied-pmid 17510418?><pub-id pub-id-type="pmid">17510418</pub-id></mixed-citation></ref><ref id="ref-36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pyrko</surname><given-names>P</given-names></name><name><surname>Kardosh</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group>:
<article-title>HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.</article-title>
<source><italic>Cancer Res.</italic></source><year>2007</year>;<volume>67</volume>(<issue>22</issue>):<fpage>10920</fpage>&#8211;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0796</pub-id>
<?supplied-pmid 18006837?><pub-id pub-id-type="pmid">18006837</pub-id></mixed-citation></ref><ref id="ref-37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Barros</surname><given-names>S</given-names></name><name><surname>Zakaroff-Girard</surname><given-names>A</given-names></name><name><surname>Lafontan</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9.</article-title>
<source><italic>J Pharmacol Exp Ther.</italic></source><year>2007</year>;<volume>320</volume>(<issue>1</issue>):<fpage>291</fpage>&#8211;<lpage>299</lpage>.
<pub-id pub-id-type="doi">10.1124/jpet.106.111849</pub-id>
<?supplied-pmid 17038510?><pub-id pub-id-type="pmid">17038510</pub-id></mixed-citation></ref><ref id="ref-38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gills</surname><given-names>JJ</given-names></name><name><surname>Lopiccolo</surname><given-names>J</given-names></name><name><surname>Dennis</surname><given-names>PA</given-names></name></person-group>:
<article-title>Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.</article-title>
<source><italic>Autophagy.</italic></source><year>2008</year>;<volume>4</volume>(<issue>1</issue>):<fpage>107</fpage>&#8211;<lpage>109</lpage>.
<pub-id pub-id-type="doi">10.4161/auto.5224</pub-id>
<?supplied-pmid 18000394?><pub-id pub-id-type="pmid">18000394</pub-id></mixed-citation></ref><ref id="ref-39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plastaras</surname><given-names>JP</given-names></name><name><surname>Vapiwala</surname><given-names>N</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name><etal/></person-group>:
<article-title>Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.</article-title>
<source><italic>Cancer Biol Ther.</italic></source><year>2008</year>;<volume>7</volume>(<issue>5</issue>):<fpage>628</fpage>&#8211;<lpage>635</lpage>.
<pub-id pub-id-type="doi">10.4161/cbt.7.5.5728</pub-id>
<?supplied-pmid 18285707?><pub-id pub-id-type="pmid">18285707</pub-id></mixed-citation></ref><ref id="ref-40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><name><surname>Burger</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.</article-title>
<source><italic>Biochem Biophys Res Commun.</italic></source><year>2008</year>;<volume>377</volume>(<issue>4</issue>):<fpage>1309</fpage>&#8211;<lpage>1314</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbrc.2008.10.167</pub-id>
<?supplied-pmid 19000651?><pub-id pub-id-type="pmid">19000651</pub-id></mixed-citation></ref><ref id="ref-41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giri</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Shaik</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in
<italic>in vitro</italic> assay design.</article-title>
<source><italic>Drug Metab Dispos.</italic></source><year>2009</year>;<volume>37</volume>(<issue>3</issue>):<fpage>560</fpage>&#8211;<lpage>70</lpage>.
<pub-id pub-id-type="doi">10.1124/dmd.108.022046</pub-id>
<!--<pub-id pub-id-type="pmcid">2680510</pub-id>-->
<?supplied-pmid 19056916?><pub-id pub-id-type="pmid">19056916</pub-id></mixed-citation></ref><ref id="ref-42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>P</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.</article-title>
<source><italic>Cancer Biol Ther.</italic></source><year>2009</year>;<volume>8</volume>(<issue>3</issue>):<fpage>226</fpage>&#8211;<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.4161/cbt.8.3.7339</pub-id>
<?supplied-pmid 19106637?><pub-id pub-id-type="pmid">19106637</pub-id></mixed-citation></ref><ref id="ref-43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dewan</surname><given-names>MZ</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Katano</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.</article-title>
<source><italic>Int J Cancer.</italic></source><year>2009</year>;<volume>124</volume>(<issue>3</issue>):<fpage>622</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1002/ijc.23993</pub-id>
<?supplied-pmid 18973272?><pub-id pub-id-type="pmid">18973272</pub-id></mixed-citation></ref><ref id="ref-44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Harvey</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Quantitative analysis of tumor vascular structure after drug treatment.</article-title>
<source><italic>Conf Proc IEEE Eng Med Biol Soc.</italic></source><year>2010</year>;<volume>2010</volume>:<fpage>726</fpage>&#8211;<lpage>729</lpage>.
<pub-id pub-id-type="doi">10.1109/IEMBS.2010.5626274</pub-id>
<?supplied-pmid 21095896?><pub-id pub-id-type="pmid">21095896</pub-id></mixed-citation></ref><ref id="ref-45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Evangelidis</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.</article-title>
<source><italic>PLoS Comput Biol.</italic></source><year>2011</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e1002037</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1002037</pub-id>
<!--<pub-id pub-id-type="pmcid">3084228</pub-id>-->
<?supplied-pmid 21552547?><pub-id pub-id-type="pmid">21552547</pub-id></mixed-citation></ref><ref id="ref-46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Alonso-Basanta</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).</article-title>
<source><italic>J Biol Chem.</italic></source><year>2011</year>;<volume>286</volume>(<issue>33</issue>):<fpage>29408</fpage>&#8211;<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M110.197665</pub-id>
<!--<pub-id pub-id-type="pmcid">3190746</pub-id>-->
<?supplied-pmid 21697087?><pub-id pub-id-type="pmid">21697087</pub-id></mixed-citation></ref><ref id="ref-47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><name><surname>Mylonas</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.</article-title>
<source><italic>Curr Cancer Drug Targets.</italic></source><year>2011</year>;<volume>11</volume>(<issue>7</issue>):<fpage>799</fpage>&#8211;<lpage>809</lpage>.
<pub-id pub-id-type="doi">10.2174/156800911796798913</pub-id>
<?supplied-pmid 21762082?><pub-id pub-id-type="pmid">21762082</pub-id></mixed-citation></ref><ref id="ref-48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>See</surname><given-names>AP</given-names></name><name><surname>Aziz</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Nelfinavir induces radiation sensitization in pituitary adenoma cells.</article-title>
<source><italic>Cancer Biol Ther.</italic></source><year>2011</year>;<volume>12</volume>(<issue>7</issue>):<fpage>657</fpage>&#8211;<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.4161/cbt.12.7.17172</pub-id>
<?supplied-pmid 21811091?><pub-id pub-id-type="pmid">21811091</pub-id></mixed-citation></ref><ref id="ref-49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Fousek</surname><given-names>K</given-names></name><name><surname>Chow</surname><given-names>WA</given-names></name></person-group>:
<article-title>Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.</article-title>
<source><italic>FEBS J.</italic></source><year>2012</year>;<volume>279</volume>(<issue>13</issue>):<fpage>2399</fpage>&#8211;<lpage>411</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08619.x</pub-id>
<?supplied-pmid 22540830?><pub-id pub-id-type="pmid">22540830</pub-id></mixed-citation></ref><ref id="ref-50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bono</surname><given-names>C</given-names></name><name><surname>Karlin</surname><given-names>L</given-names></name><name><surname>Harel</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells
<italic>in vitro</italic> and
<italic>in vivo</italic>.</article-title>
<source><italic>Haematologica.</italic></source><year>2012</year>;<volume>97</volume>(<issue>7</issue>):<fpage>1101</fpage>&#8211;<lpage>1109</lpage>.
<pub-id pub-id-type="doi">10.3324/haematol.2011.049981</pub-id>
<!--<pub-id pub-id-type="pmcid">3396684</pub-id>-->
<?supplied-pmid 22271897?><pub-id pub-id-type="pmid">22271897</pub-id></mixed-citation></ref><ref id="ref-51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Matsingou</surname><given-names>C</given-names></name><name><surname>Brem</surname><given-names>GJ</given-names></name><etal/></person-group>:
<article-title>Inhibin beta E is upregulated by drug-induced endoplasmic reticulum stress as a transcriptional target gene of ATF4.</article-title>
<source><italic>Toxicol Appl Pharmacol.</italic></source><year>2012</year>;<volume>264</volume>(<issue>2</issue>):<fpage>300</fpage>&#8211;<lpage>304</lpage>.
<pub-id pub-id-type="doi">10.1016/j.taap.2012.08.011</pub-id>
<?supplied-pmid 22935518?><pub-id pub-id-type="pmid">22935518</pub-id></mixed-citation></ref><ref id="ref-52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barillari</surname><given-names>G</given-names></name><name><surname>Iovane</surname><given-names>A</given-names></name><name><surname>Bacigalupo</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.</article-title>
<source><italic>AIDS.</italic></source><year>2012</year>;<volume>26</volume>(<issue>8</issue>):<fpage>909</fpage>&#8211;<lpage>919</lpage>.
<pub-id pub-id-type="doi">10.1097/QAD.0b013e328351f7a5</pub-id>
<?supplied-pmid 22313963?><pub-id pub-id-type="pmid">22313963</pub-id></mixed-citation></ref><ref id="ref-53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Timeus</surname><given-names>F</given-names></name><name><surname>Crescenzio</surname><given-names>N</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>
<italic>in vitro</italic> anti-neuroblastoma activity of saquinavir and its association with imatinib.</article-title>
<source><italic>Oncol Rep.</italic></source><year>2012</year>;<volume>27</volume>(<issue>3</issue>):<fpage>734</fpage>&#8211;<lpage>740</lpage>.
<pub-id pub-id-type="doi">10.3892/or.2011.1582</pub-id>
<?supplied-pmid 22159894?><pub-id pub-id-type="pmid">22159894</pub-id></mixed-citation></ref><ref id="ref-54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ismail</surname><given-names>WI</given-names></name><name><surname>King</surname><given-names>JA</given-names></name><name><surname>Anwar</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Indinavir and nelfinavir inhibit proximal insulin receptor signaling and salicylate abrogates inhibition: potential role of the NFkappa B pathway.</article-title>
<source><italic>J Cell Biochem.</italic></source><year>2013</year>;<volume>114</volume>(<issue>8</issue>):<fpage>1729</fpage>&#8211;<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1002/jcb.24513</pub-id>
<?supplied-pmid 23386514?><pub-id pub-id-type="pmid">23386514</pub-id></mixed-citation></ref><ref id="ref-55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Escalante</surname><given-names>AM</given-names></name><name><surname>McGrath</surname><given-names>RT</given-names></name><name><surname>Karolak</surname><given-names>MR</given-names></name><etal/></person-group>:
<article-title>Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib
<italic>in vitro</italic> and
<italic>in vivo</italic>.</article-title>
<source><italic>Cancer Chemother Pharmacol.</italic></source><year>2013</year>;<volume>71</volume>(<issue>6</issue>):<fpage>1567</fpage>&#8211;<lpage>76</lpage>.
<pub-id pub-id-type="doi">10.1007/s00280-013-2156-3</pub-id>
<!--<pub-id pub-id-type="pmcid">3669633</pub-id>-->
<?supplied-pmid 23572175?><pub-id pub-id-type="pmid">23572175</pub-id></mixed-citation></ref><ref id="ref-56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bociaga-Jasik</surname><given-names>M</given-names></name><name><surname>Polus</surname><given-names>A</given-names></name><name><surname>Goralska</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Metabolic effects of the HIV protease inhibitor--saquinavir in differentiating human preadypocytes.</article-title>
<source><italic>Pharmacol Rep.</italic></source><year>2013</year>;<volume>65</volume>(<issue>4</issue>):<fpage>937</fpage>&#8211;<lpage>950</lpage>.
<pub-id pub-id-type="doi">10.1016/s1734-1140(13)71075-2</pub-id>
<?supplied-pmid 24145088?><pub-id pub-id-type="pmid">24145088</pub-id></mixed-citation></ref><ref id="ref-57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cox</surname><given-names>JS</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name></person-group>:
<article-title>A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response.</article-title>
<source><italic>Cell.</italic></source><year>1996</year>;<volume>87</volume>(<issue>3</issue>):<fpage>391</fpage>&#8211;<lpage>404</lpage>.
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81360-4</pub-id>
<?supplied-pmid 8898193?><pub-id pub-id-type="pmid">8898193</pub-id></mixed-citation></ref><ref id="ref-58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Weissman</surname><given-names>AM</given-names></name></person-group>:
<article-title>The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer.</article-title>
<source><italic>Genes Cancer.</italic></source><year>2010</year>;<volume>1</volume>(<issue>7</issue>):<fpage>764</fpage>&#8211;<lpage>778</lpage>.
<pub-id pub-id-type="doi">10.1177/1947601910383011</pub-id>
<!--<pub-id pub-id-type="pmcid">3039444</pub-id>-->
<?supplied-pmid 21331300?><pub-id pub-id-type="pmid">21331300</pub-id></mixed-citation></ref><ref id="ref-59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>N</given-names></name><name><surname>Kawahara</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>mRNA splicing-mediated C-terminal replacement of transcription factor Hac1p is required for efficient activation of the unfolded protein response.</article-title>
<source><italic>Proc Natl Acad Sci U S A.</italic></source><year>2000</year>;<volume>97</volume>(<issue>9</issue>):<fpage>4660</fpage>&#8211;<lpage>4665</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.050010197</pub-id>
<!--<pub-id pub-id-type="pmcid">18289</pub-id>-->
<?supplied-pmid 10781071?><pub-id pub-id-type="pmid">10781071</pub-id></mixed-citation></ref><ref id="ref-60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sch&#246;nthal</surname><given-names>AH</given-names></name></person-group>:
<article-title>Endoplasmic reticulum stress: its role in disease and novel prospects for therapy.</article-title>
<source><italic>Scientifica (Cairo).</italic></source><year>2012</year>;<volume>2012</volume>:<fpage>857516</fpage>. Review.
<pub-id pub-id-type="doi">10.6064/2012/857516</pub-id>
<!--<pub-id pub-id-type="pmcid">3820435</pub-id>-->
<?supplied-pmid 24278747?><pub-id pub-id-type="pmid">24278747</pub-id></mixed-citation></ref><ref id="ref-61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simmons</surname><given-names>SO</given-names></name><name><surname>Fan</surname><given-names>CY</given-names></name><name><surname>Ramabhadran</surname><given-names>R</given-names></name></person-group>:
<article-title>Cellular stress response pathway system as a sentinel ensamble in toxicological screening.</article-title>
<source><italic>Toxicol Sci.</italic></source><year>2009</year>;<volume>111</volume>(<issue>2</issue>):<fpage>202</fpage>&#8211;<lpage>225</lpage>. (Review).
<pub-id pub-id-type="doi">10.1093/toxsci/kfp140</pub-id>
<?supplied-pmid 19567883?><pub-id pub-id-type="pmid">19567883</pub-id></mixed-citation></ref><ref id="ref-62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group>:
<article-title>Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells.</article-title>
<source><italic>J Chemother.</italic></source><year>2012</year>;<volume>24</volume>(<issue>3</issue>):<fpage>161</fpage>&#8211;<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1179/1973947812Y.0000000011</pub-id>
<?supplied-pmid 22759761?><pub-id pub-id-type="pmid">22759761</pub-id></mixed-citation></ref><ref id="ref-63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrich</surname><given-names>AM</given-names></name><name><surname>Leshchenko</surname><given-names>V</given-names></name><name><surname>Kuo</surname><given-names>PY</given-names></name><etal/></person-group>:
<article-title>Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.</article-title>
<source><italic>Clin Cancer Res.</italic></source><year>2012</year>;<volume>18</volume>(<issue>9</issue>):<fpage>2534</fpage>&#8211;<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1407</pub-id>
<!--<pub-id pub-id-type="pmcid">3889476</pub-id>-->
<?supplied-pmid 22338016?><pub-id pub-id-type="pmid">22338016</pub-id></mixed-citation></ref><ref id="ref-64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kast</surname><given-names>RE</given-names></name><name><surname>Halatsch</surname><given-names>ME</given-names></name></person-group>:
<article-title>Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.</article-title>
<source><italic>Arch Med Res.</italic></source><year>2012</year>;<volume>43</volume>(<issue>3</issue>):<fpage>243</fpage>&#8211;<lpage>7</lpage>. Review.
<pub-id pub-id-type="doi">10.1016/j.arcmed.2012.04.005</pub-id>
<?supplied-pmid 22564423?><pub-id pub-id-type="pmid">22564423</pub-id></mixed-citation></ref><ref id="ref-65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Mott</surname><given-names>M</given-names></name><name><surname>Xi</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Phase I study of nelfinavir in liposarcoma.</article-title>
<source><italic>Cancer Chemother Pharmacol.</italic></source><year>2012</year>;<volume>70</volume>(<issue>6</issue>):<fpage>791</fpage>&#8211;<lpage>799</lpage>.
<pub-id pub-id-type="doi">10.1007/s00280-012-1961-4</pub-id>
<!--<pub-id pub-id-type="pmcid">3904496</pub-id>-->
<?supplied-pmid 22983015?><pub-id pub-id-type="pmid">22983015</pub-id></mixed-citation></ref><ref id="ref-66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shim</surname><given-names>JS</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name><name><surname>Beebe</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.</article-title>
<source><italic>J Natl Cancer Inst.</italic></source><year>2012</year>;<volume>104</volume>(<issue>20</issue>):<fpage>1576</fpage>&#8211;<lpage>90</lpage>.
<pub-id pub-id-type="doi">10.1093/jnci/djs396</pub-id>
<!--<pub-id pub-id-type="pmcid">3472971</pub-id>-->
<?supplied-pmid 23042933?><pub-id pub-id-type="pmid">23042933</pub-id></mixed-citation></ref><ref id="ref-67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>Bader</surname><given-names>J</given-names></name><name><surname>Overkleeft</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.</article-title>
<source><italic>Blood Cancer J.</italic></source><year>2013</year>;<volume>3</volume>:<fpage>e103</fpage>.
<pub-id pub-id-type="doi">10.1038/bcj.2013.2</pub-id>
<!--<pub-id pub-id-type="pmcid">3615215</pub-id>-->
<?supplied-pmid 23454896?><pub-id pub-id-type="pmid">23454896</pub-id></mixed-citation></ref><ref id="ref-68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>M&#252;ller-Ide</surname><given-names>H</given-names></name><name><surname>R&#252;ckrich</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.</article-title>
<source><italic>Leuk Res.</italic></source><year>2014</year>;<volume>38</volume>(<issue>3</issue>):<fpage>383</fpage>&#8211;<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1016/j.leukres.2013.12.017</pub-id>
<?supplied-pmid 24418752?><pub-id pub-id-type="pmid">24418752</pub-id></mixed-citation></ref><ref id="ref-69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Darini</surname><given-names>CY</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Azoulay</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential.</article-title>
<source><italic>Cell Death Dis.</italic></source><year>2013</year>;<volume>4</volume>:<fpage>e706</fpage>.
<pub-id pub-id-type="doi">10.1038/cddis.2013.206</pub-id>
<!--<pub-id pub-id-type="pmcid">3730396</pub-id>-->
<?supplied-pmid 23828569?><pub-id pub-id-type="pmid">23828569</pub-id></mixed-citation></ref><ref id="ref-70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kast</surname><given-names>RE</given-names></name><name><surname>Boockvar</surname><given-names>JA</given-names></name><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9. by the International Initiative for Accelerated Improvement of Glioblastoma Care.</article-title>
<source><italic>Oncotarget.</italic></source><year>2013</year>;<volume>4</volume>(<issue>4</issue>):<fpage>502</fpage>&#8211;<lpage>530</lpage>.
<!--<pub-id pub-id-type="pmcid">3720600</pub-id>-->
<?supplied-pmid 23594434?><pub-id pub-id-type="pmid">23594434</pub-id></mixed-citation></ref><ref id="ref-71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Abd Elmageed</surname><given-names>ZY</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group>:
<article-title>Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.</article-title>
<source><italic>PLoS One.</italic></source><year>2014</year>;<volume>9</volume>(<issue>8</issue>):<fpage>e103109</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0103109</pub-id>
<!--<pub-id pub-id-type="pmcid">4133210</pub-id>-->
<?supplied-pmid 25121735?><pub-id pub-id-type="pmid">25121735</pub-id></mixed-citation></ref><ref id="ref-72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kushchayeva</surname><given-names>Y</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Recupero</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.</article-title>
<source><italic>J Clin Endocrinol Metab.</italic></source><year>2014</year>;<volume>99</volume>(<issue>5</issue>):<fpage>E734</fpage>&#8211;<lpage>45</lpage>.
<pub-id pub-id-type="doi">10.1210/jc.2013-3369</pub-id>
<?supplied-pmid 24483157?><pub-id pub-id-type="pmid">24483157</pub-id></mixed-citation></ref><ref id="ref-73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kushchayeva</surname><given-names>Y</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Burman</surname><given-names>KD</given-names></name><etal/></person-group>:
<article-title>Repositioning therapy for thyroid cancer: new insights on established medications.</article-title>
<source><italic>Endocr Relat Cancer.</italic></source><year>2014</year>;<volume>21</volume>(<issue>3</issue>):<fpage>R183</fpage>&#8211;<lpage>94</lpage>.
<pub-id pub-id-type="doi">10.1530/ERC-13-0473</pub-id>
<?supplied-pmid 24446492?><pub-id pub-id-type="pmid">24446492</pub-id></mixed-citation></ref><ref id="ref-74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alonso-Basanta</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Maity</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.</article-title>
<source><italic>J Neurooncol.</italic></source><year>2014</year>;<volume>116</volume>(<issue>2</issue>):<fpage>365</fpage>&#8211;<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1007/s11060-013-1303-3</pub-id>
<!--<pub-id pub-id-type="pmcid">4116080</pub-id>-->
<?supplied-pmid 24194293?><pub-id pub-id-type="pmid">24194293</pub-id></mixed-citation></ref><ref id="ref-75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buijsen</surname><given-names>J</given-names></name><name><surname>Lammering</surname><given-names>G</given-names></name><name><surname>Jansen</surname><given-names>RL</given-names></name><etal/></person-group>:
<article-title>Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer.</article-title>
<source><italic>Radiother Oncol.</italic></source><year>2013</year>;<volume>107</volume>(<issue>2</issue>):<fpage>184</fpage>&#8211;<lpage>188</lpage>.
<pub-id pub-id-type="doi">10.1016/j.radonc.2013.03.023</pub-id>
<?supplied-pmid 23647753?><pub-id pub-id-type="pmid">23647753</pub-id></mixed-citation></ref><ref id="ref-76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoover</surname><given-names>AC</given-names></name><name><surname>Milhem</surname><given-names>MM</given-names></name><name><surname>Anderson</surname><given-names>CM</given-names></name><etal/></person-group>:
<article-title>Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.</article-title>
<source><italic>Head Neck.</italic></source><year>2014</year>.
<pub-id pub-id-type="doi">10.1002/hed.23664</pub-id>
<?supplied-pmid 24596143?><pub-id pub-id-type="pmid">24596143</pub-id></mixed-citation></ref><ref id="ref-77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donia</surname><given-names>M</given-names></name><name><surname>Mangano</surname><given-names>K</given-names></name><name><surname>Fagone</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the
<italic>in vitro</italic> and
<italic>in vivo</italic> tumor formation of A375 human melanoma cells.</article-title>
<source><italic>Oncol Rep.</italic></source><year>2012</year>;<volume>28</volume>(<issue>2</issue>):<fpage>682</fpage>&#8211;<lpage>688</lpage>.
<pub-id pub-id-type="doi">10.3892/or.2012.1840</pub-id>
<?supplied-pmid 22665020?><pub-id pub-id-type="pmid">22665020</pub-id></mixed-citation></ref><ref id="ref-78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>LC</given-names></name><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin
<italic>in vitro</italic>.</article-title>
<source><italic>Am J Trop Med Hyg.</italic></source><year>2010</year>;<volume>82</volume>(<issue>1</issue>):<fpage>148</fpage>&#8211;<lpage>150</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.2010.09-0427</pub-id>
<!--<pub-id pub-id-type="pmcid">2803526</pub-id>-->
<?supplied-pmid 20065012?><pub-id pub-id-type="pmid">20065012</pub-id></mixed-citation></ref><ref id="ref-79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Golden</surname><given-names>EB</given-names></name><etal/></person-group>:
<article-title>Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.</article-title>
<source><italic>Cancer Lett.</italic></source><year>2009</year>;<volume>282</volume>(<issue>1</issue>):<fpage>87</fpage>&#8211;<lpage>97</lpage>.
<pub-id pub-id-type="doi">10.1016/j.canlet.2009.03.007</pub-id>
<?supplied-pmid 19345476?><pub-id pub-id-type="pmid">19345476</pub-id></mixed-citation></ref><ref id="ref-80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>E</given-names></name><name><surname>Maddocks</surname><given-names>K</given-names></name><name><surname>Flynn</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.</article-title>
<source><italic>Leuk Lymphoma.</italic></source><year>2013</year>;<volume>54</volume>(<issue>12</issue>):<fpage>2685</fpage>&#8211;<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.3109/10428194.2013.781168</pub-id>
<!--<pub-id pub-id-type="pmcid">3815958</pub-id>-->
<?supplied-pmid 23469959?><pub-id pub-id-type="pmid">23469959</pub-id></mixed-citation></ref><ref id="ref-81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>P</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>
Nelfinavir induces mitochondria protection by ERK &#189;-mediated mcl-1 stabilization that can be overcome by sorafenib.</article-title>
<source><italic>Invest New Drugs.</italic></source><year>2010</year>;<volume>28</volume>(<issue>5</issue>):<fpage>535</fpage>&#8211;<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1007/s10637-009-9281-1</pub-id>
<?supplied-pmid 19554262?><pub-id pub-id-type="pmid">19554262</pub-id></mixed-citation></ref><ref id="ref-82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Rahmeh</surname><given-names>M</given-names></name><name><surname>Gingelmaier</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.</article-title>
<source><italic>Mol Cancer.</italic></source><year>2010</year>;<volume>9</volume>:<fpage>19</fpage>.
<pub-id pub-id-type="doi">10.1186/1476-4598-9-19</pub-id>
<!--<pub-id pub-id-type="pmcid">2836985</pub-id>-->
<?supplied-pmid 20105315?><pub-id pub-id-type="pmid">20105315</pub-id></mixed-citation></ref><ref id="ref-83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#252;ning</surname><given-names>A</given-names></name><name><surname>Friese</surname><given-names>K</given-names></name><name><surname>Burges</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.</article-title>
<source><italic>Breast Cancer Res.</italic></source><year>2010</year>;<volume>12</volume>(<issue>4</issue>):<fpage>R45</fpage>.
<pub-id pub-id-type="doi">10.1186/bcr2602</pub-id>
<!--<pub-id pub-id-type="pmcid">2949632</pub-id>-->
<?supplied-pmid 20594311?><pub-id pub-id-type="pmid">20594311</pub-id></mixed-citation></ref><ref id="ref-84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Zielonka</surname><given-names>J</given-names></name><name><surname>McAllister</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.</article-title>
<source><italic>Br J Cancer.</italic></source><year>2014</year>;<volume>111</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1038/bjc.2014.272</pub-id>
<!--<pub-id pub-id-type="pmcid">4090735</pub-id>-->
<?supplied-pmid 24867695?><pub-id pub-id-type="pmid">24867695</pub-id></mixed-citation></ref><ref id="ref-85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheong</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.</article-title>
<source><italic>Mol Cancer Ther.</italic></source><year>2011</year>;<volume>10</volume>(<issue>12</issue>):<fpage>2350</fpage>&#8211;<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0497</pub-id>
<!--<pub-id pub-id-type="pmcid">3237863</pub-id>-->
<?supplied-pmid 21992792?><pub-id pub-id-type="pmid">21992792</pub-id></mixed-citation></ref><ref id="ref-86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben Sahra</surname><given-names>I</given-names></name><name><surname>Laurent</surname><given-names>K</given-names></name><name><surname>Giuliano</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.</article-title>
<source><italic>Cancer Res.</italic></source><year>2010</year>;<volume>70</volume>(<issue>6</issue>):<fpage>2465</fpage>&#8211;<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2782</pub-id>
<?supplied-pmid 20215500?><pub-id pub-id-type="pmid">20215500</pub-id></mixed-citation></ref><ref id="ref-87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blumenthal</surname><given-names>GM</given-names></name><name><surname>Gills</surname><given-names>JJ</given-names></name><name><surname>Ballas</surname><given-names>MS</given-names></name><etal/></person-group>:
<article-title>A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.</article-title>
<source><italic>Oncotarget.</italic></source><year>2014</year>;<volume>5</volume>(<issue>18</issue>):<fpage>8161</fpage>&#8211;<lpage>72</lpage>.
<!--<pub-id pub-id-type="pmcid">4226674</pub-id>-->
<?supplied-pmid 25327558?><pub-id pub-id-type="pmid">25327558</pub-id></mixed-citation></ref><ref id="ref-88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brunner</surname><given-names>TB</given-names></name><name><surname>Geiger</surname><given-names>M</given-names></name><name><surname>Grabenbauer</surname><given-names>GG</given-names></name><etal/></person-group>:
<article-title>Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.</article-title>
<source><italic>J Clin Oncol.</italic></source><year>2008</year>;<volume>26</volume>(<issue>16</issue>):<fpage>2699</fpage>&#8211;<lpage>2706</lpage>.
<pub-id pub-id-type="doi">10.1200/JCO.2007.15.2355</pub-id><?supplied-pmid 18509182?><pub-id pub-id-type="pmid">18509182</pub-id></mixed-citation></ref><ref id="ref-89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rengan</surname><given-names>R</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>Pryma</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.</article-title>
<source><italic>J Thorac Oncol.</italic></source><year>2012</year>;<volume>7</volume>(<issue>4</issue>):<fpage>709</fpage>&#8211;<lpage>15</lpage>.
<pub-id pub-id-type="doi">10.1097/JTO.0b013e3182435aa6</pub-id>
<!--<pub-id pub-id-type="pmcid">3310889</pub-id>-->
<?supplied-pmid 22425919?><pub-id pub-id-type="pmid">22425919</pub-id></mixed-citation></ref><ref id="ref-90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gills</surname><given-names>JJ</given-names></name><name><surname>Dennis</surname><given-names>PA</given-names></name></person-group>:
<article-title>Perifosine: update on a novel Akt inhibitor.</article-title>
<source><italic>Curr Oncol Rep.</italic></source><year>2009</year>;<volume>11</volume>(<issue>2</issue>):<fpage>102</fpage>&#8211;<lpage>10</lpage>. Review.
<pub-id pub-id-type="doi">10.1007/s11912-009-0016-4</pub-id>
<?supplied-pmid 19216841?><pub-id pub-id-type="pmid">19216841</pub-id></mixed-citation></ref><ref id="ref-91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Harkavy</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.</article-title>
<source><italic>Oncogene.</italic></source><year>2007</year>;<volume>26</volume>(<issue>13</issue>):<fpage>1932</fpage>&#8211;<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.onc.1209990</pub-id>
<?supplied-pmid 17001314?><pub-id pub-id-type="pmid">17001314</pub-id></mixed-citation></ref><ref id="ref-92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><etal/></person-group>:
<article-title>Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.</article-title>
<source><italic>Science.</italic></source><year>2005</year>;<volume>307</volume>(<issue>5712</issue>):<fpage>1098</fpage>&#8211;<lpage>1101</lpage>.
<pub-id pub-id-type="doi">10.1126/science.1106148</pub-id>
<?supplied-pmid 15718470?><pub-id pub-id-type="pmid">15718470</pub-id></mixed-citation></ref><ref id="ref-93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carracedo</surname><given-names>A</given-names></name><name><surname>Bacelga</surname><given-names>J</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name></person-group>:
<article-title>Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.</article-title>
<source><italic>Cell Cycle.</italic></source><year>2008</year>;<volume>7</volume>(<issue>24</issue>):<fpage>3805</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.4161/cc.7.24.7244</pub-id>
<!--<pub-id pub-id-type="pmcid">3130531</pub-id>-->
<?supplied-pmid 19098454?><pub-id pub-id-type="pmid">19098454</pub-id></mixed-citation></ref><ref id="ref-94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>WB</given-names></name><name><surname>Dennis</surname><given-names>PA</given-names></name></person-group>:
<article-title>Repositioning HIV protease inhibitors as cancer therapeutics.</article-title>
<source><italic>Curr Opin HIV AIDS.</italic></source><year>2008</year>;<volume>3</volume>(<issue>6</issue>):<fpage>666</fpage>&#8211;<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1097/COH.0b013e328313915d</pub-id>
<!--<pub-id pub-id-type="pmcid">2682221</pub-id>-->
<?supplied-pmid 19373040?><pub-id pub-id-type="pmid">19373040</pub-id></mixed-citation></ref><ref id="ref-95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernhard</surname><given-names>EJ</given-names></name><name><surname>Brunner</surname><given-names>TB</given-names></name></person-group>:
<article-title>Progress towards the use of HIV protease inhibitors in cancer therapy.</article-title>
<source><italic>Cancer Biol Ther.</italic></source><year>2008</year>;<volume>7</volume>(<issue>5</issue>):<fpage>636</fpage>&#8211;<lpage>637</lpage>.
<pub-id pub-id-type="doi">10.4161/cbt.7.5.6087</pub-id>
<?supplied-pmid 18421253?><pub-id pub-id-type="pmid">18421253</pub-id></mixed-citation></ref><ref id="ref-96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jhaveri</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Perillyl alcohol for the treatment of temozolomide-resistant gliomas.</article-title>
<source><italic>Mol Cancer Ther.</italic></source><year>2012</year>;<volume>11</volume>(<issue>11</issue>):<fpage>2462</fpage>&#8211;<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0321</pub-id>
<?supplied-pmid 22933703?><pub-id pub-id-type="pmid">22933703</pub-id></mixed-citation></ref><ref id="ref-97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Wilke</surname><given-names>WW</given-names></name><etal/></person-group>:
<article-title>Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT.</article-title>
<source><italic>Int J Radiat Oncol Biol Phys.</italic></source><year>2009</year>;<volume>74</volume>(<issue>3</issue>):<fpage>928</fpage>&#8211;<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.03.004</pub-id>
<!--<pub-id pub-id-type="pmcid">2766796</pub-id>-->
<?supplied-pmid 19480971?><pub-id pub-id-type="pmid">19480971</pub-id></mixed-citation></ref><ref id="ref-98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Wilke</surname><given-names>WW</given-names></name><name><surname>Taylor</surname><given-names>EN</given-names></name><etal/></person-group>:
<article-title>Signaling pathways in adenoid cystic cancers: implications for treatment.</article-title>
<source><italic>Cancer Biol Ther.</italic></source><year>2009</year>;<volume>8</volume>(<issue>20</issue>):<fpage>1947</fpage>&#8211;<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.4161/cbt.8.20.9596</pub-id>
<!--<pub-id pub-id-type="pmcid">3638238</pub-id>-->
<?supplied-pmid 19729990?><pub-id pub-id-type="pmid">19729990</pub-id></mixed-citation></ref><ref id="ref-99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danaher</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Roland</surname><given-names>AT</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors block oral epithelial cell DNA synthesis.</article-title>
<source><italic>Arch Oral Biol.</italic></source><year>2010</year>;<volume>55</volume>(<issue>2</issue>):<fpage>95</fpage>&#8211;<lpage>100</lpage>.
<!--<pub-id pub-id-type="pmcid">2818864</pub-id>-->
<?supplied-pmid 20035926?><pub-id pub-id-type="pmid">20035926</pub-id></mixed-citation></ref><ref id="ref-100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kimple</surname><given-names>RJ</given-names></name><name><surname>Vaseva</surname><given-names>AV</given-names></name><name><surname>Cox</surname><given-names>AD</given-names></name><etal/></person-group>:
<article-title>Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.</article-title>
<source><italic>Clin Cancer Res.</italic></source><year>2010</year>;<volume>16</volume>(<issue>3</issue>):<fpage>912</fpage>&#8211;<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1324</pub-id>
<!--<pub-id pub-id-type="pmcid">2818631</pub-id>-->
<?supplied-pmid 20103665?><pub-id pub-id-type="pmid">20103665</pub-id></mixed-citation></ref><ref id="ref-101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bourlier</surname><given-names>V</given-names></name><name><surname>Zakaroff-Girard</surname><given-names>A</given-names></name><name><surname>De Barros</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation.</article-title>
<source><italic>J Pharmacol Exp Ther.</italic></source><year>2005</year>;<volume>312</volume>(<issue>3</issue>):<fpage>1272</fpage>&#8211;<lpage>1279</lpage>.
<pub-id pub-id-type="doi">10.1124/jpet.104.077263</pub-id>
<?supplied-pmid 15537822?><pub-id pub-id-type="pmid">15537822</pub-id></mixed-citation></ref><ref id="ref-102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Golden</surname><given-names>EB</given-names></name><etal/></person-group>:
<article-title>Preferential killing of triple-negative breast cancer cells
<italic>in vitro</italic> and
<italic>in vivo</italic> when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.</article-title>
<source><italic>Cancer Lett.</italic></source><year>2012</year>;<volume>325</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1016/j.canlet.2012.05.030</pub-id>
<?supplied-pmid 22664238?><pub-id pub-id-type="pmid">22664238</pub-id></mixed-citation></ref><ref id="ref-103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sato</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><etal/></person-group>:
<article-title>SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis.</article-title>
<source><italic>Cell.</italic></source><year>1994</year>;<volume>77</volume>(<issue>1</issue>):<fpage>53</fpage>&#8211;<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1016/0092-8674(94)90234-8</pub-id>
<?supplied-pmid 8156598?><pub-id pub-id-type="pmid">8156598</pub-id></mixed-citation></ref><ref id="ref-104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimomura</surname><given-names>I</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><etal/></person-group>:
<article-title>Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.</article-title>
<source><italic>Genes Dev.</italic></source><year>1998</year>;<volume>12</volume>(<issue>20</issue>):<fpage>3182</fpage>&#8211;<lpage>3194</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.12.20.3182</pub-id>
<!--<pub-id pub-id-type="pmcid">317215</pub-id>-->
<?supplied-pmid 9784493?><pub-id pub-id-type="pmid">9784493</pub-id></mixed-citation></ref><ref id="ref-105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riddle</surname><given-names>TM</given-names></name><name><surname>Kuhel</surname><given-names>DG</given-names></name><name><surname>Woollett</surname><given-names>LA</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.</article-title>
<source><italic>J Biol Chem.</italic></source><year>2001</year>;<volume>276</volume>(<issue>40</issue>):<fpage>37514</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M104557200</pub-id>
<?supplied-pmid 11546771?><pub-id pub-id-type="pmid">11546771</pub-id></mixed-citation></ref><ref id="ref-106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Fousek</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>
Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6.</article-title>
<source><italic>Clin Cancer Res.</italic></source><year>2011</year>;<volume>17</volume>(<issue>7</issue>):<fpage>1796</fpage>&#8211;<lpage>806</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-3216</pub-id>
<?supplied-pmid 21355074?><pub-id pub-id-type="pmid">21355074</pub-id></mixed-citation></ref><ref id="ref-107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lenhard</surname><given-names>JM</given-names></name><name><surname>Croom</surname><given-names>Dk</given-names></name><name><surname>Weiel</surname><given-names>JE</given-names></name><etal/></person-group>:
<article-title>HIV protease inhibitors stimulate hepatic triglyceride sinthesis.</article-title>
<source><italic>Arterioscler Thromb Vasc Biol.</italic></source><year>2000</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2625</fpage>&#8211;<lpage>2629</lpage>.
<pub-id pub-id-type="doi">10.1161/01.ATV.20.12.2625</pub-id>
<?supplied-pmid 11116063?><pub-id pub-id-type="pmid">11116063</pub-id></mixed-citation></ref><ref id="ref-108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crum-Cianflone</surname><given-names>NF</given-names></name><name><surname>Hullsiek</surname><given-names>KH</given-names></name><name><surname>Marconi</surname><given-names>V</given-names></name><etal/></person-group>:
<article-title>The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients.</article-title>
<source><italic>J Acquir Immune Defic Syndr.</italic></source><year>2009</year>;<volume>51</volume>(<issue>3</issue>):<fpage>305</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1097/QAI.0b013e3181aa13c7</pub-id>
<!--<pub-id pub-id-type="pmcid">2720269</pub-id>-->
<?supplied-pmid 19412116?><pub-id pub-id-type="pmid">19412116</pub-id></mixed-citation></ref><ref id="ref-109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giardino Torchia</surname><given-names>ML</given-names></name><name><surname>Ciaglia</surname><given-names>E</given-names></name><name><surname>Masci</surname><given-names>AM</given-names></name><etal/></person-group>:
<article-title>Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.</article-title>
<source><italic>PLoS One.</italic></source><year>2010</year>;<volume>5</volume>(<issue>6</issue>):<fpage>e11052</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0011052</pub-id>
<!--<pub-id pub-id-type="pmcid">2883582</pub-id>-->
<?supplied-pmid 20548796?><pub-id pub-id-type="pmid">20548796</pub-id></mixed-citation></ref><ref id="ref-110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lucia</surname><given-names>MB</given-names></name><name><surname>Anu</surname><given-names>R</given-names></name><name><surname>Handley</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi&#8217;s sarcoma cells.</article-title>
<source><italic>Br J Cancer.</italic></source><year>2011</year>;<volume>105</volume>(<issue>4</issue>):<fpage>513</fpage>&#8211;<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1038/bjc.2011.275</pub-id>
<!--<pub-id pub-id-type="pmcid">3170973</pub-id>-->
<?supplied-pmid 21829205?><pub-id pub-id-type="pmid">21829205</pub-id></mixed-citation></ref><ref id="ref-111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia</surname><given-names>MG</given-names></name><name><surname>Alaniz</surname><given-names>LD</given-names></name><name><surname>Cordo Russo</surname><given-names>RI</given-names></name><etal/></person-group>:
<article-title>PI3K/Akt inhibition modulates multidrug resistance and activates NF-&#954;B in murine lymphoma cell lines.</article-title>
<source><italic>Leuk Res.</italic></source><year>2009</year>;<volume>33</volume>(<issue>2</issue>):<fpage>288</fpage>&#8211;<lpage>296</lpage>.
<pub-id pub-id-type="doi">10.1016/j.leukres.2008.06.010</pub-id>
<?supplied-pmid 18640717?><pub-id pub-id-type="pmid">18640717</pub-id></mixed-citation></ref><ref id="ref-112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hui</surname><given-names>DY</given-names></name></person-group>:
<article-title>Effects of HIV protease inhibitor therapy on lipid metabolism.</article-title>
<source><italic>Prog Lipid Res.</italic></source><year>2003</year>;<volume>42</volume>(<issue>2</issue>):<fpage>81</fpage>&#8211;<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1016/S0163-7827(02)00046-2</pub-id>
<?supplied-pmid 12547652?><pub-id pub-id-type="pmid">12547652</pub-id></mixed-citation></ref><ref id="ref-113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>You</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy.</article-title>
<source><italic>Cancer Sci.</italic></source><year>2010</year>;<volume>101</volume>(<issue>12</issue>):<fpage>2644</fpage>&#8211;<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01724.x</pub-id>
<?supplied-pmid 20946116?><pub-id pub-id-type="pmid">20946116</pub-id></mixed-citation></ref><ref id="ref-114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maksimovic-Ivanic</surname><given-names>D</given-names></name><name><surname>Mijatovic</surname><given-names>S</given-names></name><name><surname>Miljkovic</surname><given-names>D</given-names></name></person-group>:
<article-title>The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.</article-title>
<source><italic>Mol Cancer Ther.</italic></source><year>2009</year>;<volume>8</volume>(<issue>5</issue>):<fpage>1169</fpage>&#8211;<lpage>78</lpage>.
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0998</pub-id>
<?supplied-pmid 19417156?><pub-id pub-id-type="pmid">19417156</pub-id></mixed-citation></ref><ref id="ref-115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yorimitsu</surname><given-names>T</given-names></name><name><surname>Nair</surname><given-names>U</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group>:
<article-title>Endoplasmic reticulum stress triggers autophagy.</article-title>
<source><italic>J Biol Chem.</italic></source><year>2006</year>;<volume>281</volume>(<issue>40</issue>):<fpage>30299</fpage>&#8211;<lpage>304</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M607007200</pub-id>
<!--<pub-id pub-id-type="pmcid">1828866</pub-id>-->
<?supplied-pmid 16901900?><pub-id pub-id-type="pmid">16901900</pub-id></mixed-citation></ref><ref id="ref-116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name></person-group>:
<article-title>Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.</article-title>
<source><italic>Urology.</italic></source><year>2012</year>;<volume>79</volume>(<issue>4</issue>):<fpage>966.e13</fpage>&#8211;<lpage>966.e21</lpage>.
<pub-id pub-id-type="doi">10.1016/j.urology.2011.11.033</pub-id>
<?supplied-pmid 22296623?><pub-id pub-id-type="pmid">22296623</pub-id></mixed-citation></ref><ref id="ref-117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McLean</surname><given-names>K</given-names></name><name><surname>VanDeVen</surname><given-names>NA</given-names></name><name><surname>Sorenson</surname><given-names>DR</given-names></name><etal/></person-group>:
<article-title>The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells.</article-title>
<source><italic>Gynecol Oncol.</italic></source><year>2009</year>;<volume>112</volume>(<issue>3</issue>):<fpage>623</fpage>&#8211;<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ygyno.2008.11.028</pub-id>
<?supplied-pmid 19147209?><pub-id pub-id-type="pmid">19147209</pub-id></mixed-citation></ref><ref id="ref-118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawabata</surname><given-names>S</given-names></name><name><surname>Gills</surname><given-names>JJ</given-names></name><name><surname>Mercado-Matos</surname><given-names>JR</given-names></name><etal/></person-group>:
<article-title>Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.</article-title>
<source><italic>Cell Death Dis.</italic></source><year>2012</year>;<volume>3</volume>:<fpage>e353</fpage>.
<pub-id pub-id-type="doi">10.1038/cddis.2012.87</pub-id>
<!--<pub-id pub-id-type="pmcid">3406586</pub-id>-->
<?supplied-pmid 22825471?><pub-id pub-id-type="pmid">22825471</pub-id></mixed-citation></ref></ref-list></back><sub-article id="report8788" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.6594.r8788</article-id><title-group><article-title>Referee response for version 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Br&#252;ning</surname><given-names>Ansgar</given-names></name><xref ref-type="aff" rid="r8788a1">1</xref><role>Referee</role></contrib><aff id="r8788a1">
<label>1</label>Molecular Biology Laboratory, University Hospital Munich, Munich, Germany</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>1</day><month>6</month><year>2015</year></pub-date><related-article id="d35e8165" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.5827.2">Version 2</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>This is a highly informative and comprehensive review on our current knowledge about the anti-cancer mechanism of nelfinavir. It also deals with the pros and cons of a possible repurposing of nelfinavir (and other HIV PIs) for cancer treatment.</p><p>The following amendments and corrections are suggested:</p><p>Proteasome: In the abstract, the proteasome is listed among the factors to be &#8220;down-regulated&#8221; by nelfinavir. Is the proteasome &#8220;downregulated&#8221; or &#8220;inhibited&#8221; in its activity?&#160; This might be a slight semantic inaccuracy but is important because it reflects different molecular mechanisms. The same applies to Akt, which, according to the author, is mentioned to be &#8220;inhibited&#8221; in some phrases and to be &#8220;downregulated&#8221; (as a protein?) by nelfinavir in other phrases.</p><p>Independent of this, there is also a controversy in the literature about the ability of nelfinavir to inhibit proteasomal activity. Some authors observed inhibition of proteasomal enzyme activity by HIV PIs, whereas proteasomal target genes such as HIFalpha and cyclins have unexpectedly not been described to accumulate in the presence of PIs. Instead, as mentioned in this review, several of these proteasomal target proteins were found to be downregulated by nelfinavir treatment.</p><p>Using yeast terminology (HAC1) to introduce human ER stress mechanisms might confuse the reader.</p><p>Fig.1: How does ER stress lead to proteasome inhibition?</p><p>I have problems with the author&#8217;s proposed classification of PIs into ER stress inducers and Akt inhibitors (Abstract and Conclusion). Ritonavir is listed as an ER stressor only (conclusions &#8220;9&#8221;), but has been identified by several researchers to cause both ER stress and Akt inhibition. Furthermore, according to our experience, the ability of PIs to reduce Akt activity appears to be dependent on the cell line(s) used. Our group also observed enhanced Akt phosphorylation by nelfinavir in cell lines with low endogenous Akt activity, and Akt activation is also a known response to ER stress.</p><p>A combination of nelfinavir with mTOR inhibitors is suggested by the author. There are some independent recent reports indicating that nelfinavir also acts as an mTOR inhibitor.</p><p>The ability of nelfinavir to induce oxidative stress should be mentioned, because this may represent one of the reasons why nelfinavir may exert ER stress or other anti-cancer effects. (Fig. 2, for example, suggests undefined &#8220;protease inhibition&#8221; as the only mechanism of nelfinavir-induced ER stress).</p><p>Some typos in the text and in the figures should be corrected (hidroxychloroquine; phosphorilation; endothelial (=endoplasmic?) reticulum; Bc12 (=bcl2? Fig. 5)).</p><p>I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body><sub-article id="comment1409" article-type="response"><front-stub><contrib-group><contrib contrib-type="author"><name><surname>Koltai</surname><given-names>Tomas</given-names></name><aff>Centro de Diagnostico y Tratamiento OSPIA Zona Norte, Argentina</aff></contrib></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests</p></fn></author-notes><pub-date pub-type="epub"><day>3</day><month>6</month><year>2015</year></pub-date></front-stub><body><p>Thank you for your deep and knowledgeable revision of this manuscript. I agree with you about the inaccuracies mentioned and there will be corrected in a third version of the article.</p><p>Of course, down-regulation and inhibition in the molecular world are two different things, so it is wise to make the modifications you suggested: proteasome is inhibited and not down-regulated by NFV. Akt, being a protein is down-regulated and not inhibited. These will be modified in version 3.</p><p>Yeast terminology for proteins playing a role in proteosomal stress may be confusing, so it will be changed for proteins found in mammalian proteosomal stress.</p><p>The classification of PIs according their main anticancer activity is based on clinically achievable concentration of the drug. It is quite possible (I found no experimental evidence so far) that at very high concentrations,&#160;PIs are both ER stressors and Akt down-regulators. But at doses used in the clinical setting the classification I propose may represent actual differences between the different PIs.</p><p>Oxidative stress will be mentioned in version 3. I agree it is an important cause of ER stress.</p><p>Amendments will be made to figure 5 along with the remarks you kindly made.</p><p>The association of NFV and mTOR inhibitors showed interesting results in naturally occurring squamous cell tumors in dogs in our experience (unpublished data). This probably means some sort of synergy between the two. This synergy is mentioned by many authors. NFV acting on mTOR will be particularly highlighted.</p><p>Thank you for your interesting revision. All issues you mentioned will be considered in version 3 of this article.</p></body></sub-article></sub-article><sub-article id="report7500" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.6229.r7500</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pecci</surname><given-names>Adali</given-names></name><xref ref-type="aff" rid="r7500a1">1</xref><role>Referee</role></contrib><aff id="r7500a1">
<label>1</label>Catedra de quimica biologica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>2</month><year>2015</year></pub-date><related-article id="d35e8274" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.5827.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The article by Koltai reviews the extensive literature concerning Nelfinavir as an anti-cancer drug. Overall the study makes a good update of the evidences of nefilnavir anti-cancer activity and its role in controlling ERS-UPR pathway.&#160;It would be interesting to include in the discussion information about &#160;the different trials that are currently carry on with Nelfinavir in different tumors.</p><p>I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body></sub-article></article>